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Chronic inflammation in the central nervous system (CNS) is thought to play a role in 
learning and memory deficits that are prevalent in neurodegenerative diseases such as 
Alzheimer’s disease (AD) (Rosi et al. 2005). The association between 
neuroinflammation and learning and memory deficits were investigated. Below are a 
summary of the findings of the present work. 
 
1. Acute peripheral administration of lipopolysaccharide (LPS), a bacteria cell wall 
proteoglycan, is unable to elicit spatial learning and object recognition deficits 
when tested 24 hours after administration. This contradicts what was previously 
reported where a single acute dose of LPS was sufficient to induce a cognitive 
deficit in rodents.  
 
2. A spatial learning and object recognition memory deficits were observed in 
animals dosed with the increasing LPS dose regime. This is the first time that 
peripheral administration of LPS was shown to be able to elicit an object 
recognition deficits in rats. During the time of test, animals did not exhibit any 
sickness behaviour. This strengthens the hypothesis that the cognitive impairment 
observed were devoid of confounding factors such as sickness behaviour. 
 
3. The increasing LPS dosing regime was shown to elicit a neuroinflammatory 
response where elevated tumour necrosis factor α (TNFα) and major 
histocompatibility complex II (MHCII) were observed in both hippocampus and 
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cortex even after the completion of the treatment. The continuous inflammatory 
response seen is specific only to the CNS as peripheral system TNFα expression 
was only shown to be elevated only after the first dose of LPS and returned to the 
basal level in subsequent doses. 
 
4. The LPS treatment induced several changes that may serve to explain the 
cognitive deficits observed. In the hippocampus, an increase in amyloidogenesis, 
demonstrated by the increase in amyloid precursor protein (APP). Furthermore, 
LPS treatment may affect glutamatergic transmission, cholinergic innervations 
and also synaptic plasticity. The alteration of these properties in neural networks 
may be associated with the cognitive deficits observed and illustrate the role of 
neuroinflammation in AD. 
 
5. The effect of the LPS treatment is not limited to an acute effect. When the animals 
were tested 8 to 12 weeks post LPS treatment, a similar spatial learning deficit. 
This suggests that there exist a critical window where a delayed cognitive 
impairment can be observed. This deficit could be due to the alteration in the 




   INTRODUCTION 
 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are examples of 
neurodegenerative diseases that are becoming more prevalent in today’s population. 
While the etiology of each disease may differ, there is a common defining characteristic 
in which inflammation is present in most neurodegenerative diseases. For example, acute 
phase reactants proteins, cytokines, complement components and other inflammatory 
mediators that are associated with local inflammatory response are commonly found 
surrounding the characteristic β-amyloid deposits in AD patients (Akiyama et al. 2000). 
Elevated levels of proinflammatory cytokines, urpegulation of inducible nitric oxide 
synthase (iNOS), cyclooxygenase 2 (COX2) and activated microglia were similarly 
observed in PD patients in the substantia nigra and striatum (Whitton 2007). However, 
neuroinflamation in these disorders were previously viewed as an epiphenomenon, where 
damaged neurons are able to induce proinflammatory response via glia cells (Skaper 
2007). 
 
Numerous data has challenged this idea and are indicative that neuroinflammation may 
play a more prominent role in the onset in addition to disease progression. In the CNS, 
glial cells, in addition to providing support to neuronal function, serve to respond to stress 
and insults by transiently upregulating inflammatory processes. Under normal 
circumstances, these responses are kept in check by other endogenous anti-inflammatory 
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and neuroprotective mechanisms (Skaper 2007). In the diseased brain however, the 
dysregulation of the glial cells, in a self perpetuating manner (Block et al. 2007), 
inevitably promotes severe and chronic neuroinflammation that could lead to 
degeneration of the neurons which is now widely touted as the neuroinflammation 
hypothesis (Griffin et al. 1998).  
 
Hence, one of the key objectives of this project is to recapitulate the neuroinflammation 
component that is prevalent in most neurodegenerative diseases in a rodent model to 
study the effect of chronic inflammation on learning and memory as cognitive deficits are 
a key feature in most neurodegenerative diseases. 
 
1.1 Cells involved in neuroinflammation 
1.1.1 Microglia 
Microglia is generally found throughout the CNS and plays an integral part of the 
immune defence. These cells account for approximately 20% of the total glial population 
(Kreutzberg 1995) and in the adult mice, they predominate in the grey matter with the 
highest concentrations being found in the hippocampus, olfactory telencephalon, basal 
ganglia and substantia nigra (Block et al. 2007). They have a mesodermal origin and 
belong to the monocyte macrophage lineage. Under normal conditions, the resting 
microglia, with its ramified structure, is able to move and survey the environment to 
detect for any changes in the surrounding area, thus acting as the CNS first line of 
immune defence (Gao and Hong 2008). In the event of an immunogenic stimuli or injury, 
the microglia is activated and functions similar to a macrophage. It was postulated that 
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the activated microglia could be functionally discerned into two states, namely the 
phagocytic phenotype (innate activation) or an antigen presenting phenotype (adaptive 
activation) that could ultimately determine the range of cytokines that are produced 
(Town et al. 2005). The activation of the microglia are accompanied by a significant 
morphology change (ameboid shape where the cells undergo shortening of cellular 
processes and enlargement of the soma). These activated microglia are able to 
phagocytose cellular debris or foreign materials. At the same time, they produce 
chemokines to attract more microglia, cytokines and factors that promotes microglia 
proliferation (Gehmann 1995). Furthermore, the activated microglia also up-regulate a 
myriad of cell surface antigens such as MHC type I and II, cluster of differentiation (CD) 
4 and ectodermal dysplasia (ED) 1 (Schoeter et al. 1999).  
  
Tightly regulated neuroinflammation is beneficial for recovery under certain 
circumstances. For instance, microglia have been shown to stimulate myelin repair, 
eliminate toxic proteins and avert neurodegeneration (Gao and Hong 2008). However the 
problem arises when regulations of these inflammatory processes are derailed. Under 
such conditions, the activated microglia produce significantly large amount of cytotoxic 
factors such as superoxide (O2
.-
), nitric oxide (NO) and tumour necrosis factor-α (TNFα) 
(Block et al. 2007). This excessive, uncontrolled inflammation, that induce an increase in 
cytotoxic factors, if left uncheck, could produce considerable bystander damage to 




1.1.2  Astrocytes 
Astrocytes were long believed to be structural cells as they make up to about 50% of 
human brain volume. However in recent years, astrocytes have been shown to serve 
many housekeeping functions, including maintenance of the extracellular environment 
and stabilization of cell-cell communications in the CNS. Characterised by its star-shaped 
cells, these cells are important for amino acid, nutrient and ion metabolism in the brain, 
coupling of neuronal activity and cerebral blood flow and modulation of excitatory 
synaptic transmission (Margakis and Rothstein 2006).  
 
In the diseased state such as in multiple sclerosis and AD, activated astrocytes, are 
believed to facilitate leukocyte recruitment to the CNS by increasing leukocyte adhesion 
molecules and chemokine production (Moynagh 2005). It is difficult to tease out the 
contribution of astrocytes in inducing chronic neuroinflammation as it is functionally 
intertwined with other cell types. However, there are evidences from genetic mutations in 
astrocytes able to mimic certain neurodegenerative diseases. For instance, in cells 
expressing the familial AD persenilin 1 mutation, calcium oscillations were found to 
occur at lower ATP and glutamate concentrations than in wild-type astrocytes, supporting 
the idea that the change in calcium signalling between astrocytes could ultimately 
contribute to dysfunction of neurons in a diseased state (Margakis and Rothstein 2006). 
 
More interestingly, similar to microglia, stimulation of γ-interferon (IFNγ) in vitro was 
shown to be able to increase the expression of MHC type I and II antigens in astrocytes. 
Furthermore, it has been shown that lipopolysaccharide (LPS) is able to stimulate 
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astrocytes to produce prostaglandins, complements C3 and factor B, and cytokines 
(Liebermann et al. 1989). These observations suggest that astrocytes may play an 
important role during immunological response as it shares many important functional 
characteristics with macrophages. 
 
1.2 Neuroinflammation and cognition 
1.2.1 Effect of cytokine on cognition 
Excessive activation of the glial cells such as microglia and astrocytes induced a 
significantly higher production of cytokines such as interleukin (IL)-1β and TNFα (Block 
et al. 1997). Elevation of cytokines has been associated with cognitive deficits where in 
AD and mild cognitive impairment patients, a stage described as a preclinical stage of 
AD and is applied as a transitional period between normal aging and early AD, an 
increased in inflammatory cytokines were observed in blood samples (Magaki et al. 2007, 
Guerreiro et al. 2007). Furthermore, it was recently reported that an increase in TNFα 
induced by acute and chronic inflammation were associated to a decrease in the 
performance of AD patients in cognitive tasks (Holmes et al. 2009). In PD patients, 
elevated levels of IL-6 were also observed in the nigrostriatal region and cerebrospinal 
fluid (CSF) (Hofmann et al. 2009). In addition, transgenic animals that overexpressed IL-
6 exhibit neuropathological changes that are closely correlated with the cognitive deficit 
seen (Akiyama et al. 2000), thus suggesting a possible correlation between inflammation 
and cognitive deficits. 
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Under normal physiological conditions however, these cytokines may play an important 
role in cognitive processes. In animal models using TNF knock out animals, it has been 
shown that TNFα is essential for normal functions of learning and memory. These 
animals under immunologically non-challenged conditions, performed significantly 
worse in cognition tasks (Baune et al. 2008). In addition, under specific conditions, TNFα 
may play a role against neuronal death where TNFα treatment can protect against focal 
cerebral ischemia (Nawashiro et al. 1997). In vitro, TNFα through the activation nuclear 
factor kappa B (NFκB) may protect neurons against metabolic, excitotoxic or oxidative 
insults by upholding maintenance of intracellular Ca
2+
 homeostatsis and inhibition of 
reactive oxygen species (ROS) (Pickering and O’Conner 2007). The dysregulation of 
microglia and astrocytes, leading to the excessive production of pro-inflammatory 
cytokines, has since been suggested to prevent the proper function of normal cognitive 
processes to the extent of dire consequences. 
 
Many labs have tried to induce cognitive deficits in rodent model by increasing the levels 
of cytokines in the CNS. In rodents, Oitzl et al. (1993) had shown that direct 
intracerebroventricular (ICV) infusion of IL-1β was able to induce a transient deficit in 
rodent spatial learning and memory task such as the Morris water maze (MWM). 
Although animals treated with IL-1β did not show any deficit in acquiring the location of 
the platform, they were unable to recall the location of the hidden platform, when tested 
24 hours later.  
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Not limited to centrally infused cytokine, peripheral administration of cytokine was also 
shown to be able to induce cognitive deficit. The intraperitoneal (IP) injection of 100ng 
IL-1β was shown to be effective in disrupting spatial learning and memory (Gilbertini et 
al. 1995). Mice treated with IL-1β showed a significantly higher latency in finding the 
hidden platform location. It was hypothesized that the administration of IL-1β 
significantly affected memory acquisition suggesting that centrally and peripherally 
administerions of IL-1β may have differing effect on learning and memory. IL-1β was 
also shown to induce a deficit on long-term memory in contextual fear (Pugh et al. 1998). 
These neuroinflammatory mediators have been shown to be able to induce cognitive 
deficit through several mechanisms that affect the cell survival and neuronal properties. 
 
1.2.2 Effect of inflammation on long term potentiation 
Long term potentiation, a form of synaptic plasticity that is widely touted as a model of 
learning and memory is characterized by a persistent enhancement of neurotransmission 
following an appropriate stimulus (Kerchner and Nicoll 2008). There is evidence to 
suggest that cytokines are able to abrogate the action of LTP where peripheral LPS 
injection is able to impair LTP in the hippocampus (Vereker et al. 2006). LPS has been 
shown to be able to impair LTP through IL-1β activated pathway by increasing the 
activity of the stress-activated kinases, c-Jun N-terminal kinase (JNK) and p38 mitogen-
activated protein kinase (MAPK) by increasing the phosphorylation of these kinases, 
ultimately leading to the impairment in neuronal function (O’Donnell et al. 2000).  
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LPS was also shown to disrupt glutamate release by the activation of p38 and NFκB 
(Kelly et al. 2003). As glutamate is an important player in the propagation of LTP, 
disruption of glutamate release will inevitably lead to the impairment of LTP. By 
studying the glutamate release in synaptosomes of dentate gyrus from rats treated with 
IL-1β, it was shown that IL-1β reduces the amount of glutamate release after being 
tetanised. SB203580, a p38 inhibitor was able to fully reverse this effect (Kelly et al.  
2003). In addition, peripheral administration of an immunogenic property such as LPS is 
sufficient to induce, not only neuroinflammation but also impairment in LTP that is 
reflected in the cognitive deficit observed in animal behaviour tests. 
 
1.2.3 Effect of inflammation on neurite outgrowth 
Activation of microglia has also been shown to induce cell death at high concentrations 
of endotoxins such as LPS and advanced glycation endproducts (AGEs) in vitro (Münch 
et al. et al. 2003). Albeit it is known that activated microglia is able to produce various 
factors that are cytotoxic. However, the exact mechanism through which these reactive 
glial cells induce neuronal death is not completely understood. At a sublethal dose of LPS 
or AGEs, it was reported that these immunogenic properties were able to induce 
activation of microglia that can lead to a reduction of neurite outgrowth (Münch et al. 
2003). More specifically, TNFα has been shown to reduce neurite outgrowth and 
branching in the hippocampal neurons via small GTPase Rho proteins (Neumann et al. 
2002). The reduction of neurite outgrowth during a mild inflammation (with an absence 
of T cell amplified systemic inflammation) with factors secreted by the activated 
microglia could interfere with the cytoskeleton reorganization. This change in synaptic 
 11 
reorganization is sufficient to induce learning and memory deficits even in the absence of 
cell death (Gallagher et al. 1996).  The reduction of neurite outgrowth has since then been 
linked to NO and NO-derived products. NO can directly regulate actin reorganization in 
the neurite, by inducing signaling cascades involved in growth cone collapse and through 
regulation of gene transcription (Münch et al. 2003). 
 
1.2.4 Effect of inflammation on oxidative stress generation 
Oxidative stress is a prevalent feature in numerous neurodegeneration diseases albeit the 
source of ROS is still debatable (Block et al. 2007). In the microglia, the ROS production 
is catalysed by the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
enzyme complex that converts oxygen to superoxide. Distributed in both the cell 
membrane and membrane of organelles, the ROS generated under normal conditions has 
some beneficial functions as ROS generation plays a vital role in host defense. ROS are 
involved in cell defence against pathogens, but also in reversible regulatory processes in 
most cells and tissues (Bedard and Kraus 2007). Hence, like the proinflammatory 
cytokines as discussed previously, the beneficial or detrimental effect of ROS lies on a 
fine balance. 
 
In normal aging humans, the level of ROS increases with age as predicted by the “free-
radical theory of aging” (Harman 1956) and this increase in ROS levels is usually 
accompanied by a decline in cognitive and motor functions although not associated with 
a significant loss of neurons (Dröge and Shipper 2007). Furthermore, a decrease in 
antioxidant enzymes and concentrations of small-molecular-weight antioxidants in blood 
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and tissue cells, also induce an age-dependent elevation in the proportion of ROS and 
free radicals that are normally being “removed” (Wei and Lee 2002). The involvement of 
NADPH oxidases in aging has been linked to the increased level of ROS in the CNS 
(Krause 2006). More interestingly neural damage induced by extracellular secretion of 
ROS has been shown to be mediated by NADPH oxidase through the activation of 
microglia (Walder et al. 1997). These oxidative conditions are able to induce irreversible 
damage to proteins, lipids, carbohydrates and nucleic acids. 
 
In AD and PD patients, NADPH oxidases were reported to be upregulated in the CNS 
(Block et al. 2007). In addition to the reduction in the concentrations of antioxidants 
present in the system, most patients suffering from AD and PD also experience an 
increase in ROS production, further uncoupling the redox balance in the CNS. The 
excessive ROS in the system could ultimately trigger the mitochondrial apoptosis 
pathway, inducing a mitochondrial dysfunction by the release of cytochrome C into the 
cytoplasm (Dean 2008). Thus, during chronic neuroinflammation, the increase in ROS 
production induced by the upregulation of ROS producing enzymes is able to induce 
cognitive deficits as the excessive ROS produced is able to trigger the apoptotic pathway 
that culminates with neuronal death. 
 
The generation of ROS, is reported to act as a common signaling mechanism for 
phagocytes where the gangliosides activate microglia through protein kinase C and 
NADPH oxidase (Min et al. 2004). Furthermore, changes in the morphology and 
proliferation of microglia (microgliosis) are regulated by hydrogen peroxide produced 
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from NADPH oxidase (Block et al. 2007). In return, higher levels of ROS in the 
intracellular positively regulate the inflammatory response where an increase production 
of pro-inflammatory response is able to affect cell survival by increasing lipid 
peroxidation and protein nitration (Engelhardt et al. 2001). Hence, it seems that the 
catalytic events of NADPH oxidase in the activated microglia are essential contributors 
of oxidative stress and inflammation that in extreme conditions could lead to neuronal 
damage and ultimately affect cognitive ability. 
 
1.2.5 Effect of inflammation on neurogenesis 
Neuroinflammation has also been shown to induce a blocakade in neurogenesis (Monje et 
al. 2003). Neurogenesis refers to the birth of new neurons that occur within the CNS. In 
the hippocampus, the birth of these new neurons continues throughout life and the 
amount of neurogenesis correlates closely with the hippocampal functions of learning and 
memory (Monje et al. 2003). Any disruption to the environment of these proliferating 
neural stem or progenitor could lead to a disruption of neurogenesis and ultimately 
cognitive deficits. For example, in patients receiving therapeutic cranial radiation therapy 
a decline in cognitive function has been reported as the therapy is known to ablate any 
cell proliferation in the CNS (Monje and Palmer 2003). To illustrate the effect of an 
altered microenvironment using a rodent model, peripheral administration of LPS, 
inducing an increase in central pro-inflammatory cytokine production, was sufficient to 
induce a 35% decrease in hippocampal neurogenesis (Monje et al. 2003). This disruption 
of neurogenesis by LPS was also shown to be able to induce spatial learning and memory 
deficits task (Wu et al. 2007).  
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The direct mechanism as to how neuroinflammation is able to induce a disruption to 
neurogenesis has yet to be fully elucidated. However it is hypothesised that inflammatory 
cytokines such as IL-6 and TNFα were able to indirectly inhibit cell proliferation and 
neurogenesis in the dentate gyrus by increasing the levels of circulating glucocorticoids 
via centrally stimulating the hypothalamic-pituitary adrenal (HPA) stress axis (Vallières 
et al. 2002). It was suggested that glucocorticoids could affect cell proliferation by 
directly repressing the transcription of cyclin D1, a common cell-cycle regulator that 
controls G1-S phase transition, by binding to the promoter and affecting the β-
catenin/TCF pathway (Boku et al. 2009). 
 
In a separate study, it was also suggested that peripheral administration of LPS could 
induced cognitive deficits via COX-2. An increase in COX-2 expression in the granular 
cell layer and blood vessels, areas that are known to be neurogenic in the dentate gyrus 
was observed after LPS treatment. The involvement of COX-2 was associated with a 
decrease in newborn cell survival but not cell differentiation where the number of 5-
bromo-2-deoxyuridine (BrdU) labelled cells decreased significantly after LPS treatment 
(Bastos et al. 2008). COX-2 may modulate neurogenesis in the dentate gyrus through the 
generation of prostaglandins such as prostaglandin (PG) E2 and PGD2 that are able to 
induce apoptosis in a variety of cell types (Bastos et al. 2008). However, the involvement 
in COX-2 in reducing cell proliferation is still under investigation as other studies have 
reported that the reduction of the number of newborn neurons were associated with 
neuronal differentiation rather than neuronal proliferation. Inflammatory mediators such 
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as IL-6, TNFα and IL-18 were reported to induce an increase in glial differentiation (Liu 
et al. 2005, Cacci et al. 2008). This suggests the complexity of the effect of 
neuroinflammation in neurogenesis in the dentate gyrus. 
 
1.3 Neuroinflammation as a neurodegenerative disease model 
Neuroinflammation is a common feature in most neurodegenerative diseases. Elevated 
levels of cytokines have been seen in most AD and PD patient and these cytokines have 
been shown to have an effect on cognition. Furthermore transgenic animals that 
overexpressed specific cytokines such as IL-6 and TNFα have been shown to perform 
worse in cognitive tasks (Akiyama et al. 2000). 
 
Therefore, one of the main objectives of this project was to mimic this 
neuroinflammation in the rodent model, in order to recapitulate the cognitive deficits that 
are prevalent in neurodegenerative diseases. In order to do that, LPS was used to induce 
inflammation in the CNS. LPS is known to stimulate the immune system through the 
activation of macrophage-like cells in peripheral tissues (Takeda and Akashi 2004). LPS 
is recognised by the CD14/toll-like receptor (TLR) 4 signal transduction receptor 
complex expressed by microglia and astrocytes in the CNS (Rosi et al. 2006). TLR4
-/-
 
mice have shown reduced susceptibility to sepsis with systemic administration of LPS 
(Poltrorak et al. 1998). 
 
The TLR family consists of 10 members (TLR1-TLR10) where the cytoplasmic portion 
of TLRs displayed similarity to the IL-1 receptor family which is now also known as 
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Toll/IL-1 receptor (TIR) domain. Unlike the IL-1 receptors, the TLRs bear leucine-rich 
repeats in the extracellular domain (Takeda and Akira 2004). The TLR4 upon activation 
by LPS triggers a signaling cascade that ultimately induces the transcription of 
inflammatory cytokines such as TNF-α and IL-6 via NF-κB as shown from the schematic 
diagram (figure 1.1). 
 
Infusion of LPS into the fourth ventricle in young rats produced a chronic 
neuroinflammation with an activation of microglia and astrocytes within the 
hippocampus, piriform and entorhinal cortex. (Hauss-Wegrzyniak et al. 1998). Chronic 
infusion of LPS was also shown to induce the expression of IL-1β, TNF-α and β-amyloid 
precursor protein mRNA levels in the hippocampus. Furthermore, these animals 
displayed impaired hippocampal-dependent memory task such as the T-maze but not 
object recognition memory (Hauss-Wegrzyniak et al.1998). 
 
Peripheral administration of LPS was also able to elicit similar cognitive deficits. In a 
study conducted by Arai et al. (2001), LPS, administered intraperitoneally (IP), was able 
to elicit a deficit on spatial learning performance in the water maze. The LPS treated 
animals had a higher escape latency and path length compared to the vehicle treated 
animals and at the same time performed much worse in the Y-maze test. Hence, this 
suggests that systemic administration of LPS could induce neuroinflammation in the CNS 
mediated by the activation of microglia. These activated microglia would in turn produce 
inflammatory mediators such as cytokines to drive the cognitive impairment as seen in 
centrally administered LPS. 
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Figure 1.1 Schematic diagram of activation of TLR4 and its signalling cascade in 





Earlier experiments using LPS were conducted two to four hours after LPS injection 
(Arai et al. 2001, Gibertini et al. 1995, Sparkman et al. 2005) during which most animals 
treated with LPS were exhibiting sickness behaviour.  Sickness behaviour is generally 
associated with a lack of motivation, an increased stress or anxiety response, decreased 
locomotor activity, decreased reward activities, anorexia and a marked activation of HPA 
stress axis (Cunningham and Sanderson 2008). All the behaviours stated are able to 
confound behavioural results. These studies have made contradictory claims on the effect 
of LPS in inducing cognitive deficits. The contradictory results reported could arise due 
to the misinterpretation of the sickness behaviour as a deficit in the behavioural test 
  
This project tries to elucidate whether systemic infection induced by peripheral LPS 
administration is able to induce cognitive deficits in rodent learning and memory tasks 
that are devoid of any confounding factors such as sickness behaviour. LPS is chosen as 
an agent to induce neuroinflammation as it has been previously shown to be efficacious 
in activating the microglia in the CNS and inducing a host of inflammatory response that 
are similar to most neurodegenerative diseases. In addition, systemic induction of 
inflammation was chosen over a centrally induced inflammation as peripheral LPS 
administration is less invasive.  
 
Furthermore, potential mechanisms in which a systemic infection is able to drive changes 
in the CNS were also investigated. The effects of inflammation on several key proteins 
that are involved in the learning and memory processes were investigated. This may thus 
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explain the possible mechanisms that neuroinflammation may induce cognitive deficits. 
As neuroinflammation normally precedes cognitive deficits in AD, this may thus offer 
certain enlightenment as what is occurring in the diseased brain. 
 
Lastly, this project aims to examine whether the effect of the peripheral LPS 
administration is temporary and/or whether there is a delayed deficit that could be 
detected several weeks post treatment. A delayed deficit could suggest a potential link to 
the disruption of the neurogenesis process as newborn neurons were shown to be 
preferentially recruited in spatial learning and memory tasks (Kee et al. 2007). The 
alteration of learning and memory induced by neurogenesis may underlie the need to look 
for possible therapeutic treatment based on the complex nature of the memory deficits 





MATERIAL AND METHODS 
 
2.1 Animals 
Male Lister Hooded rats were obtained from Harlan, UK. Animals were housed four to 
five rats per cage in a temperature (20 ± 1 C) and humidity (40 ± 2%) controlled 
environment on a twelve-hour light/dark cycle (lights on 7:30am), with ad libitum access 
to food and water. Prior to all experiments, rats were habituated to the testing rooms for a 
week. All experiments were carried out in accordance with the Singapore National 
Advisory Committee for Laboratory Animal Research (NACLAR) guidelines for the use 
and care of animals for scientific purposes and GlaxoSmithKline animal research ethical 
standards.  
 
2.2 Behavioural analysis 
2.2.1 Morris water maze 
The watermaze apparatus consists of a white fibreglass pool (diameter: 1.7m, height: 
0.65m) housed in a custom built room. Extramaze cues such as screens, posters and other 
objects (e.g. lamps) were placed on the walls of the room, to help in the formation of a 
spatial map. The location of the objects remained unchanged throughout the experiments. 
The water was pre-heated so that the final water temperature was maintained at 26ºC ± 
1ºC. A litre of opacifier (Syntran ® 5905, Yeochem Singapore) was added into the water 
prior to the start of the experiment to make the water opaque. The pool was divided into 
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four imaginary quadrants, namely North, South, East and West. The platform (diameter-
20cm) was placed in the centre of one of the four quadrants and the location remains 
fixed throughout the training session for each rat. The platform, located 2cm beneath 
water surface, remains invisible to the rat while swimming. A video camera was 
positioned directly above the pool to directly feed data such as latency, pathlength and 
swim speed by using the Watermaze
TM
 software (Actimetrics Inc., USA) 
 
In each study, ten animals were allocated into each group based on the visual cue 
performance. At the start of each trial, the animals were placed into the water maze tank 
facing the wall of the maze at a random location. A typical training consists of 1 day of 
visual cue (VC) training followed by 4 days of spatial cue (SC) training. 
 
In the VC training (4 trials), a curtain is drawn around the pool, effectively hiding the 
extra maze spatial cues. A black cylindrical object (visual cue) is placed 40cm above the 
platform. The animals were allowed to use the visual cue to locate the platform location. 
Once the platform was located, the trial is stopped and the rat is left on the platform for 
thirty seconds. 
 
In the SC training, the curtain is removed, hence revealing the extra-maze cues. SC 
training performance was assessed over four days (4 to 6 trials per day). The starting 
positions for each trial were randomized and each rat was allowed to search the platform 
for two minutes, after which it would be guided to the platform. When the platform was 
found, the trial was stopped and the rat was left on the platform for thirty seconds. 
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2.2.2 Novel Object Recognition: One hour temporal model 
Animals were handled (8 to 10 minutes each) for two days before the T1 trial in the 
observation cage (Tecniplast, UK) to reduce novelty-induced stress. Objects used in these 
studies were custom made black acrylic cubes and cylinders (Labman Design, Singapore). 
A small magnet was embedded at the bottom of each object to prevent the animals from 
moving the objects during trials. 
 
2.2.2.1 T1 trial 
All animals were first habituated to an empty observation cage for two minutes. The 
animals were then briefly moved to an adjacent cage, while two identical objects were 
placed in the observation cage. The objects were placed at the front of the cage and at 
equal distances from both sides, in order to allow the rat to freely explore the objects, but 
yet at the same time allowing the experimenter to observe the rats carefully. The rats 
were then returned to the observation cage and were observed for another three minutes. 
The total time spent exploring each object was scored on-line by a trained observer and 
the video data was recorded. 
 
2.2.2.2 T2 trial 
The animals were again habituated in the observation cage for two minutes, one hour 
after the T1 trial. This is followed by the presentation of one novel and one familiar 
objects for three minutes. Objects were assigned using a randomized procedure to ensure 
treatment groups were balanced for novel object and position (left or right). Total 
exploration for each object was scored on-line and video data was recorded. The 
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discrimination index (d2) was calculated by subtracting the novel from familiar 
exploration divided by total exploration time (novel-familiar/total exploration). Object 
exploration was only scored when the animal’s nose or mouth was in direct contact with 
either object. Climbing or resting on the objects was excluded. 
 
2.2.3 Fear conditioning 
All studies were performed using eight automated video-based fear conditioning (FC) 
systems (MED Associate, USA). Prior to training, all chambers were calibrated to ensure 
that the conditioning tone intensity (for cued FC) and shock currents (for both cued and 
contextual FC) were consistent across all chambers. 
 
2.2.3.1 Hyperalgesia test 
The rats were habituated to the FC test chambers for three minutes prior to the delivery of 
the shock to reduce novelty-induced stress. Thereafter, rats were given a 0.5mA foot 
shock. The shock responses of rats were scored by another observer who was unaware of 
the treatment groups: 1 - no response to the foot shock, 2 - the animal freezes for a 
moment, 3 - the animals were startle for a while, 4 – all four paws of the animals were 
lifted from the ground and jumps for a moment and 5 – all four paws of the animals were 
lifted from the ground and jumps vigorously for a while. 
 
2.2.3.2 Cued fear conditioning 
The experiment was conducted over a period of three days. On the first day, animals were 
habituated to the FC chambers for five minutes. On the second day, the animals were 
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trained to associate a mild foot shock (unconditioned stimulus -US) with an auditory tone 
(conditioned stimulus- CS). To create a novel olfactory context, the chambers were wiped 
with 3% acetic acid. Rats were given a five-minute habituation which is followed by a CS 
(2kHz, 90dB, 5s). The US (0.5mA foot shock, 1s duration) was then co-terminated with 
the CS. Animals were then left in the chambers for an additional thirty seconds before 
returning to their home cages. On the final day, the contextual environment was altered 
by wiping down the chambers with 3% ammonium hydroxide solution and changing the 
patternless panel to polka dotted panel. Animals were then returned to their respective 
chambers (same chamber on the second day) and were habituated for two minutes. This 
is followed by the presentation of 3 minutes CS tone, during which the total amount of 
time animals spent freezing were scored by the software. An animal is considered to have 
frozen when there is an absence of all movements, except those relating to respiration. 
 
2.2.3.3 Contextual fear conditioning 
Prior to the start of the experiment, the chambers were wiped down with 3% acetic acid. 
The animals were then habituated in the chambers for five minutes before being shocked 
(6 x 0.5s, 0.8mA, inter shock interval of 1 minute). After the completion of the shocks, 
the animals were left in the chamber for an additional 30 seconds before being returned to 
the home cage. Forty eight hours later, the animals were returned to the test chambers and 
were observed for ten minutes. Prior to this, the chambers were once again wiped down 
using 3% acetic acid to ensure that the context was similar to the previous day. The 
animals were then returned to the home cage before being re-tested in the same 
conditions 24 hours later to determine the extinction rate. As was done previously, the 
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total amount of time spent freezing during the ten minutes were extracted and analysed 
using Video freeze software (Med Associate, USA). 
 
2.2.4 Laboratory animal behaviour observation registration and analysis (LABORAS™) 
General behaviour such as locomotion, grooming, rearing and immobility can be 




, Belgium) software. The LABORAS
TM
 
system catalogues these behaviours by using vibrations generated on the force 
transducers due to the movements of each animal. The signal recorded could then be 




Prior to test, all LABORAS
TM
 kits were calibrated.  The animals were placed into 
LABORAS
TM
 kits and were observed for half an hour. Food and water were available ad 




The animals’ motor-coordination were assessed using the rotarod apparatus (Linton 
Instrumentation, UK) by testing the animals’ ability to stay on a rotating rod through 
successive five minutes trials at increasing speed. Before the actual test, the animals were 
pretrained on the rotarod at low speed (4 - 5rpm) for 120s. The animals were then 
returned to their home cages. During the actual test, the animals were placed on the 
rotarod with increasing speed (4 to 40rpm). The amount of time animals spent on the 
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rotarod was recorded. Each animal was tested three times in quick succession and the 
sum total of the time spent on the rotarod was used. 
 
2.2.6 Body temperature monitoring 
Body temperature was recorded using a rectal digital thermometer probe (Bioseb, France) 
at the same time each day (8-9am) to minimize any variation due to the circadian rhythm.   
 
2.2.7 Body weight and food consumption 
The animals were weighed at the same time everyday (8 – 9am). The amount of food 
consumed was monitored by measuring the food pellet that was left on the feeder each 
day at the same time (8 – 9am). The average amount of food consumed by each rat was 
calculated by taking the total amount of food consumed divided by the number of animals 
in that cage. 
 
2.3 Biochemical analysis 
2.3.1 Enzyme linked immunosorbent assay (ELISA) 
Animals were euthanized using pentobarbital (300mg/ml/animal, IP, Age D’or, 
Singapore) two hours after the LPS/PBS treatment. In-house data demonstrated that the 
TNFα level reads its peak at two hours after LPS injection. Cardiac puncture were 
performed to collect blood samples in microtainer tube containing EDTA two hours after 
treatment. Plasma samples were separated by centrifuge at 10 000g at 4°C for 10 mins 
and stored at -20°C until use.  
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ELISA was conducted using Quantikine® kits (R&D Systems, USA) specific for rat 
TNFα/TNFSF1A according to manufacturer’s instruction. In brief, all reagents were 
brought to room temperature before the experiment. The TNFα control and standards 
were prepared. 50μl diluent was added to each well followed by an equal amount of 
sample. The plate was then incubated for 2h at room temperature (RT). The plate was 
then aspirated and washed for 5 times with the wash buffer. 100μl of TNFα conjugate 
was then added to each well and was incubated for 2h at RT.  This was followed by 
another five times wash with the wash buffer. The substrate solution containing hydrogen 
peroxide and tetramethylbenzidine (TMB) were added to the wells and incubated at RT 
for 30min. To quench the reaction, 100μl of stop solution was added and mixed 
thoroughly. The absorbance at 450nm and 570nm was then measured within 15min after 
the addition of the stop solution using the microplate reader thermo multiskan Ascent 
(Labsystems, USA). The amount of TNFα is determined by absorbance value (A570-A450) 
and compared to the standard curve to obtain the corresponding concentration value. 
 
2.3.2 Myeloperoxidase activity 
To determine microglia activity in the CNS (hippocampus) and neurotrophil activity in 
the peripheral tissue (spleen), the myeloperoxidase (MPO) activity assay was conducted 
as previously described with modification (Bhatia et al. 2003). In brief, animals were first 
perfused with saline before the respective tissues were harvested and stored at –80°C 
freezer. To extract the enzyme, the tissues were thawed at 4°C. For the spleen, due to its 
weight, these tissues were homogenised using a Polytron homogenizer in 20mM sodium 
phosphate buffer (pH 7.4). For the hippocampus however, the tissue was lysed using 
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tissue lyser (Qiagen, UK) in 20mM sodium phosphate buffer (pH 7.4). The homogenate 
was centrifuged at 13000g at 4°C for 10min. The pellet obtained was resuspended in 
50mM sodium phosphate buffer (pH 6.0) with 5% hexadeacylmethylammonium bromide 
(Sigma, USA). The resultant suspension was then subjected to four rapid freeze-thaw 
cycles. After that, the suspension was sonicated for a total time of 30s using the autogizer 
(Tomtec, USA). The suspension was then centrifuged again at 13000g for 10min at 4°C 
and the supernatant was used in the for the subsequent MPO assay. The reaction mixture 
consists of the extracted enzyme, 1.6mM TMB, 80mM sodium phosphate buffer (pH 5.4) 
and 0.3mM hydrogen peroxide (Sigma, USA). It is then incubated at 37°C for 2 min. To 
stop the reaction, 3% acetic acid of equal volume was added into the reaction mixture. 
The absorbance was then measured at 450nm using the multiskan Ascent microplate 
reader (Labsystems, USA). The results were expressed as fold increase over control 
group.  
 
2.3.3 Western blot 
2.3.3.1 Whole lysate preparation 
Brain regions of interest were dissected and lysed in lysis buffer using the tissue lyser 
(Qiagen, UK).  The lysate was then spun for 13000rpm at 4°C for 15min. The 
supernatant was collected for Western blot analysis. 
 
2.3.3.2 Synaptosome preparation 
Dissected brain regions of interest were homogenised in 0.32M sucrose in HEPES buffer 
using tissue lyser (Qiagen). The lysate was then centrifuged at 800g for 10min at 4°C. 
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The supernatant was collected and spun at 13000 rpm at 4°C for 30min. The pellet was 
then resuspended in ice cold RIPA buffer before western blot analysis. 
 
2.3.3.3 Bicinchoninic acid (BCA) protein assay 
Protein concentration was determined using the BCA protein assay kit (Thermo Scientific, 
USA) according to manufacturer’s instruction. In brief, the working reagent containing 
sodium carbonate, sodium bicarbonate, bicinchoninic acid, cupric sulfate and sodium 
tartate was mixed with the homogenate. The mixture was incubated at 37°C for 30min. 
All samples were then measured for their absorbance using a microplate reader thermo 
multiskan Ascent (Labsystems, USA) at 560nm. The total amount of protein present was 
determined using a standard curve. 
 
2.3.3.4 Western blot analysis 
Loading buffer (4X) was added to each sample (3mg/mL) solution and denatured for 5 
min at 95°C. Electrophoresis was conducted at 150V for 1.5h on 4-12% Bis-Tris Nupage 
gel (Invitrogen, USA). The gel was then transferred onto the nitrocellulose (NC) 
membrane at 20V for 1h. The NC membrane was then placed in blocking buffer (3% 
non-fat milk in phosphate buffered saline (PBS), (Sigma, USA) and was incubated at RT 
for 1h to prevent non-specific binding. This was followed by incubating the membrane 
with primary antibody (1:1000) in blocking buffer at RT for 1h. The membrane was then 
washed 6 x 5min. The infrared secondary antibody was diluted in the wash buffer 
(1:10000) and incubated again at RT for 1h in the dark. The membrane was given another 
6 x 5min washes. The membrane was then imaged using Odyssey (LiCor, USA) system, 
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quantified and analysed using the Odyssey 3.0 software to obtain the luminosity and 
intensity of the bands. 
 
2.4 Morphological analysis 
2.4.1 Immunohistochemistry 
Animals were euthanized using pentobarbital (300mg/ml/animal, IP, Age D’or, 
Singapore) and were perfused with 100ml of sterile saline followed by equal amount of 
freshly prepared 4% formaldehyde. Brains were then removed and post-fixed in 4% 
formaldehyde overnight followed by dehydration in 30% sucrose solution. Samples were 
kept in the 30% sucrose until use.  
 
Prior to sectioning, the dehydrated samples were frozen in a slurry of ethanol and dry ice 
before being left at -20°C chamber for 30min. Thirty μm coronal sections were obtained 
using the cryostat (Leica, Germany). Sections were then transferred to poly-L-lysine 
coated slides for immunohistochemistry. 
 
For immunohistochemistry, the primary antisera were prepared in PBS containing 0.01% 
triton-X100 and 5% serum albumin obtained from the secondary antibody host species. 
The secondary antisera were prepared in PBS containing 5% serum albumin. 
 
The slides were first incubated in 0.3% triton-X100 at RT for 5min to unmask antigen of 
interest. The slides were then washed for 15min in PBS and incubated in blocking 
solution (10% serum albumin from the secondary antibody host diluted in PBS) for one 
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hour. This step prevents the binding of primary antibody to non-specific antigen. The 
primary antisera were then added and incubated overnight at RT. 
 
The slides were then washed twice in PBS for 15min and then incubated for 1h in 
seconday antisera. The slides were washed in PBS for 4min and allowed to air dry at 





mounting medium and viewed using an Olympus
TM
 BX61 epifluorescence microscope. 
 
2.5 Chemicals and compounds 
2.5.1 LPS treatment 
Bacterial lipopolysaccharide (LPS E.Coli 055:B5, Sigma) in PBS was administered via 
intraperitoneal injection at 1ml/kg. The dosing regime for each study is as followed 
 
Single dose LPS                     : 1mg/kg, single dose 
Three doses LPS                     : 3 doses of 1mg/kg LPS, once daily for 3 days 
Sub chronic constant dose      : 20 doses of 1mg/kg LPS, twice daily for 10 days 
Sub chronic increasing dose   : Twice daily for 10 days as shown below (adapted and   
                                                  modified from Chen et al. 2005) 
 










AM 0.25 0.25 0.5 0.5 1 1 2 4 8 16 




2.5.2 Indomethacin administration 
Indomethacin (Sigma, USA) was administered once daily 15min prior to the LPS 
injection for ten days (1mg/kg, IP, in 0.3% sodium bicarbonate, 10 days). Control 
animals were given 0.3% sodium bicarbonate.  
 
2.5.3 Antibodies 
The following antibodies and working concentrations were used; mouse anti-rat CD11b 
(1:200), mouse anti-rat synaptophysin (1:1000, Sigma, USA) Texas Red (1:200, Vector 
laboratories, USA), FITC conjugate (1:200, Jackson Laboratory, USA), Arc (1:200 Santa 
Cruz, Singapore), VAChT (1:200 Santa Cruz, Singapore), APP (1:200 Santa Cruz, 
Singapore), and TNFα (1:200 Santa Cruz, Singapore) 
 
2.6 Statistical analysis 
All graphs were prepared using GraphPad Prism
TM 
(version 5.0) and all data are 
expressed as means ± SEM. Statistical analysis was performed using StatSoft Statistica
TM
 
(version 8.0) and all data was checked for normality prior to analysis. 
 
For the water maze, body temperature, ELISA, the daily performance of the treatment 
groups was analysed using repeated-measures ANOVA followed by planned comparison. 
For NOR, a one-way ANOVA followed by Fisher LSD post-hoc analysis for group 
comparisons was used to compare treatment groups versus vehicle groups for the T1 trial. 
For the d2 index; a repeated-measures ANOVA followed by Fisher’s LSD (plank) post-
hoc comparison test was used to compare familiar versus novel object per treatment 
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group in the T2 trial. For the LABORAS, the individual five minutes time bins was 
analysed using repeated-measures ANOVA followed by panned comparison. For the 
rotarod and western blot, an independent T-test followed by Dunnet post-hoc analysis for 







3.1 Effect of LPS treatment in inducing cognitive deficits in rodent learning and 
memory tasks 
As previously described, peripheral LPS treatment has been associated with cognitive 
deficits that can be detected in rodent learning and memory tasks such as the MWM. 
Preliminary studies were conducted to identify a suitable dosing regime that is able to 
elicit a cognitive deficit. 
 
3.1.1 Effect of single acute LPS (1mg/kg) treatment  
Arai et al. (2001) and Sparkman et al. (2005) have previously shown that a single IP dose 
of LPS was sufficient to induce a deficit in the MWM and Y-maze task in mice. To 
recapitulate the results seen by Arai et al. (2001) in rats, animals were dosed with either 
LPS (1mg/kg) or vehicle and were subsequently tested in the MWM. However, LPS is 
known to be able to induce sickness behaviour that may confound the performance of the 
animals in behaviour tasks. Animals were rested for 24h before any behavioural tasks to 
ensure that the LPS treated animals were physiologically no different from vehicle treated 
animals instead of being tested 6h after LPS treatment as was done by Arai et al. (2001).  
 
Peripheral administration of 1mg/kg of LPS did not affect the spatial learning and 
memory of rodents. When tested in the MWM, no significant effect of the LPS treatment 
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in latency (figure 3.1a), swim speed (figure 3.1b) and path length (figure 3.1c) was 
detected.  
 
Object recognition memory was then investigated using the novel object recognition 
tasks. From figure 3.2 and 3.3, no significant object recognition memory was observed. 
Both treatment groups spent significantly more time exploring the novel object (figure 
3.3), suggesting that the animals remembered the familiar objects and spend a 
significantly higher amount of time exploring the novel object. Animals displayed no 
significant difference in exploring the objects (figure 3.2b) suggesting that LPS treatment 
did not significantly affect the motivation of the animals from performing the task. A lack 
of sickness behaviour during the time of the test was also observed.  
 
To ensure that the animals were devoid of any physiological changes induced by sickness 
behaviour, the overall behaviour of the animals were observed using the LABORAS™ 
system and core body temperature were monitored 2 and 24h after treatment. Based on 
the LABORAS™ data (figure 3.4 and 3.5), at two hours after treatment, the LPS 
treatment seemed to affect certain behaviours. The LPS treated animals spent a 
significantly higher percentage of time immobilised while reducing the amount of time 
spent on locomotion and rearing. A significantly lower body temperature was also 
observed in animals treated with 1mg/kg LPS (figure 3.6) when measured 2h after LPS 
treatment, indicating the aforementioned sickness behaviour. However when the animals 
were monitored 24h later at the time in which the cognitive tests were conducted, there 
was no difference in the physiological response of the animals when tested in the 
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LABORAS and body temperature. To further ensure that the motor coordination of the 
LPS treated animals were not compromised, animals were also tested using rotarod. 
When the animals were tested 24h after the LPS treatment, no significant difference was 
observed, suggesting that the LPS treatment did not compromise the motor coordination 
of the animals (figure 3.7). 
 
3.1.2 Effect of three doses of LPS (1mg/kg, 3 days, once daily) treatment  
As single 1mg/kg LPS was unable to induce a cognitive deficit, the lack of efficacy was 
hypothesised to be due to the insufficient levels of LPS. In subsequent experiments, the 
amount of LPS delivered was increased. The LPS treatment was increased to three daily 
doses of LPS (1mg/kg) over a period of three days. 
 
Based on the water maze data, no spatial learning and memory deficit was observed in 
animals treated with LPS using this dosing regime (figure 3.8). However, judging on the 
results on SC day 1 and SC day 2 for latency and pathlength (figure 3.8a and c), the LPS 
treated animals performed slightly worse compared to the vehicle treated animals. 
 
To ensure that the animals did not suffer from sickness behaviour at the time of test, the 
core body temperature was used as a surrogate measure to determine the effect of LPS 
treatment in general behaviour. Animals displayed a significantly lower body temperature 
when tested 2h after LPS treatment that subsided on subsequent treatment days (figure 
3.9) similar to what was previously seen in the animals treated with an acute 1mg/kg of 
LPS.  
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Animals were also tested in the rotarod. Based on the results, no significant difference 
was observed between two groups, implying that during the time of test, the motor 
coordination of the rodents were unaffected by LPS treatment (figure 3.10). 
 
3.1.3 Effect of twenty doses of LPS (1mg/kg, 10 days, twice daily) treatment  
When tested in the MWM, the effect of LPS treatment was absent as no significant 
difference was observed in latency, swimspeed and pathlength (figure 3.11). The lack of 
treatment effect may arise from rats developing tolerance to the repeated dosing of LPS.  
 
3.1.4 Effect of increasing dose of LPS (0.25 to 16 mg/kg, 10 days, twice daily) treatment  
In order to prevent endotoxin tolerance from developing, an increasing dose of LPS was 
given to rats using a dosing regime by Chen et al. (2005). Due to an increase in dose 
concentration and duration, animals were given more time to recover from the side effect 
of LPS treatment to 40h. When tested in the MWM, LPS treated rats showed a spatial 
learning deficit on SC day 1 as demonstrated by the longer escape latency and pathlength 
while there was no significant difference in swim speed (figure 3.12). The vehicle treated 
animals had a steeper learning curve when compared to LPS treated animals as the LPS 
treated animals took much longer time to remember the location of the platform (figure 
3.13). However on subsequent days, LPS treated animals performed as well as vehicle 
treated animals as there was no significant difference in the latency and pathlength on SC 
day 2 to SC day 4, suggesting that the spatial memory remains intact. 
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 To determine whether spatial memory was the only memory domain that was affected by 
the increasing LPS dosing regime, animals were also tested in NOR. Based on the T1 
trial results, both treatment groups spent an equal amount of time exploring the objects, 
suggesting that there was no difference in the motivation of the animals to explore the 
objects (figure 3.14a). When animals were tested one hour later in T2, the vehicle treated 
animals spent a significantly more time exploring the novel object as compared to the 
familiar object. The LPS treated animals however, spent an equal amount of time 
exploring both novel and familiar objects (figure 3.15a). Based on the D2 index that 
normalised the effect to the total time spent exploring both objects, the vehicle treated 
animals were able to remember which objects they had seen previously. However the 
LPS treated animals were unable to remember which objects they had seen previously 
and spent an equal amount of time exploring both familiar and novel objects (figure 
3.15b). Therefore, the increasing dose of LPS treatment induced an object recognition 
deficit that has not been reported prior to this. 
 
In addition to this, LPS treated animals were also tested in a fear conditioning paradigm. 
Previous study has shown that LPS is able to elicit allodynia in rodents (Danzter 2004). 
Hence a blind study to determine the fear responses to the electrical shock were 
conducted to ensure the increasing LPS dosing regime did not induce allodynia. The 
results demonstrated that there was no significant difference in the fear response to the 
electrical shock between LPS and vehicle treated animals (figure 3.16a).  
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In the cued fear conditioning, rats are required to learn the associations between the cue 
(CS) with the shock (US). When LPS treated animals were tested in the cued fear 
conditioning paradigm, there was essentially no difference in the response between the 
LPS and vehicle treated group (figure 3.16b). The LPS treatment failed to induce any 
cognitive deficits in the cued fear conditioning paradigm signifying that peripheral LPS 
treatment did not induce any disruption in the amygdala dependent fear learning (Philip 
and LeDoux 1992). 
 
In the contextual fear conditioning, rats are required to associate the shock to their 
environment. Similarly, when the LPS treated animals were returned to the test chamber 
24h later, the freezing was recorded over a period of 10 min. In the first four minutes, 
there were no significant difference between the LPS and vehicle animals, suggesting that 
both groups were able to associate the environment and the shock received the previous 
day (figure 3.16c). However, the vehicle animals demonstrated a steeper reduction in the 
percentage of freeze. By the end of the tenth minute, the percentage of freeze observed 
was similar to the beginning of the test. On the other hand, LPS animal spent more time 
freezing throughout the ten minutes of the recall trial. In total, the LPS treated animals 
froze more than 50% of the time compared to 20% in vehicle animals. 
 
To ensure that the animals had fully recovered from the side effect of LPS treatment, a 
battery of tests were conducted to monitor the overall behaviour, motor coordination and 
core body temperature. 
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The overall general behaviour of the rodents was investigated using LABORAS™. The 
rats were monitored 2h after the first dose of LPS at 0.25mg/kg. Based on figure 3.17, at 
2h after a low dose of 0.25mg/kg LPS, LPS treated animals showed significant difference 
in behaviours such as locomotion, immobilisation and rearing. Animals spent less time in 
locomotion and rearing. They also spent more time immobilised. Hence, even at a low 
dose of LPS, it was sufficient to induce sickness behaviour that was described previously. 
 
 At the end of the increasing LPS dosing regime, animals were examined once again. 
There was no significant difference observed in the general behaviours (locomotion, 
rearing and immobilisation) of LPS animals when compared to the vehicle treated 
animals, suggesting that the sickness behaviour component observed previously was 
tolerated by the end of the 10 days dosing regime (figure 3.18). 
 
The core body temperatures were recorded throughout the ten days of dosing. Previously, 
it has been shown that the LPS treatment induced a significant reduction of body 
temperature after the first dose of LPS treatment at 1mg/kg. Similarly, in the increasing 
LPS dosing regime, the first dose of LPS treatment at 0.25mg/kg induced a hypothermic 
effect in the treated animals (2h after treatment). On subsequent treatment, the animals 
showed no difference in their core body temperature compared to the vehicle treated 
animals (figure 3.19). The reduction of body temperature after LPS treatment has also 
been previously observed where systemic injection of LPS could increase the possibility 
for development of a hypothermic response rather than fever at ambient temperatures 
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below 30°C as a regulated adaptive strategy against immunological challenge (Akarsu 
and Mamuk 2007). 
 
Finally, the effect of the increasing LPS dosing regime was also tested in the rotarod to 
determine whether the LPS treatment had elicit a disruption in motor coordination. The 
LPS treated animals displayed similar motor coordination and motivation as vehicle 
treated animals with similar amount of time spent on the rotarod (figure 3.20). 
 
Similar to results obtained from the single acute dose of LPS, the overall general 
behaviour suggest that at 40h after the completion of the dosing regime, the animals were 
devoid of any potential side effects that could confound the results obtained in the 
cognitive tests. Based on the results obtained from the previous results, the learning and 
memory deficits seen, could be attributed to the ability of the animals to tolerate the 
sickness behaviour component by repeatedly dosing the animals with LPS over a period 
of ten days (as seen from the 20 doses of 1mg/kg LPS over a period of 10 days) but was 
still sufficient to drive the cognitive deficits.  
 
However, the increasing LPS dose regime, does has its caveats. LPS has previously been 
shown to produce an anorexic effect (Dantzer 2004). Therefore, the weight changes of 
animals were monitored during the ten days of treatment. At the beginning of the 
treatment, a significant weight loss that is reflected by a reduction in food consumption, 
indicative of the anorexia induced by sickness behaviour, was observed (figure 3.21). 
However, by day 4, the animals seemed to have recovered from the LPS treatment and 
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showed similar weight gain with the vehicle treated animals. However at the higher doses 
(e.g. 16mg/kg) the LPS animals showed a stabilised weight without further increase or 
decrease, while the vehicle animals continue to gain weight. The stabilisation of the 
weight during the last few days of treatment is also reflected in a reduction in the food 
consumption but to a lesser extend as to what was seen earlier in the treatment regime. 
However, as soon as LPS treatment was completed, the LPS treated animals shown an 




















































































































Figure 3.1 Effect of single dose of LPS (1mg/kg) on (A) escape  latency  (B) swimming 
speed and (C) pathlength to find the hidden platform in the Morris watermaze test. Data 
































































Figure 3.2 Effect of single dose of LPS (1mg/kg, IP) on NOR T1 (A) trial objects 





















































Figure 3.3 Effect of single dose of LPS (1mg/kg, IP) on NOR T2 trial novel and familiar 
objects (A) exploration time and (B) discrimination (d2) index. Data points represent 
























































































































































Figure 3.4 Effect of single dose (1mg/kg) of LPS on (A) locomotion (B) time spent 
immobilised and (C) rearing using the LABORAS™ at two hours after LPS treatment. 
Data points represent mean  SEM. Asterisks indicate significantly different from the 
















































































































































Figure 3.5 Effect of single dose (1mg/kg) of LPS on (A) locomotion (B) time spent 
immobilised and (C) rearing using the LABORAS™ at 24 hours after LPS treatment. 




























 Figure 3.6 Effect of single dose of LPS (1mg/kg) on body temperature (°C). Data points 




































Figure 3.7 Effect of single dose of LPS (1mg/kg) on rotarod (s). Data points represent 






















































































































Figure 3.8 Effect of three doses of LPS (1mg/kg, once daily for three days) on (A) 
escape  latency  (B) swimming speed and (C) pathlength to find the hidden platform in 















































Figure 3.9 Effect of three doses of LPS (1mg/kg, once daily for three days) on body 
temperature. Data points represent mean  SEM. Asterisks indicate significantly different 



































Figure 3.10 Effect of three doses of LPS (1mg/kg, 3 days) on rotarod (s). Data points 

















































































































Figure 3.11 Effect of constant dose of LPS (1mg/kg, twice daily for ten days) on 
(A)escape  latency  (B) swimming speed and (C) pathlength to find the hidden platform 























































































































Figure 3.12 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) escape  latency  (B) swimming speed and (C) pathlength to find the hidden platform 




























Figure 3.13 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
escape latency required to find the hidden platform in Morris watermaze test performance. 
Data points represent mean  SEM. Asterisks indicate significantly different from the 

























































Figure 3.14 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
NOR T1 trial (A) objects exploration time (B) trial exploration time. Data points 



























































Figure 3.15 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
NOR T2 trial novel and familiar (A) objects exploration time (B) discrimination (d2) 
index. Data points represent mean  SEM. Asterisks indicate significantly different from 























































































































Figure 3.16 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) 
(A) on hyperalgesia. Animals were scored based on the shock response by an observer 
that was unaware of the treatment groups (B) cued fear conditioning (C) contextual fear 
conditioning. Data points represent mean  SEM. Asterisks indicate significantly 































































































































































Figure 3.17 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) locomotion (B) time spent immobilised and (C) rearing using the LABORAS™ at 
two hours after the first LPS treatment (0.25mg/kg). Data points represent mean  SEM. 
Asterisks indicate significantly different from the vehicle group (* p<0.05, **p<0.01, 






























             











































Figure 3.18 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) locomotion (B) time spent immobilised and (C) rearing using the LABORAS™ 40 
hours after the last LPS treatment. Data points represent mean  SEM. Asterisks indicate 


























































Figure 3.19 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
body temperature. Data points represent mean  SEM. Asterisks indicate significantly 



































Figure 3.20. Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) 
on rotarod (s). Data points represent mean  SEM. n=5. 
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Figure3.21 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) body weight and (B) amount of food consumed (g/day/animal). Data points represent 
mean  SEM. Asterisks indicate significantly different from the vehicle group (* p<0.05, 





3.2 Effect of LPS treatment in inducing inflammation 
3.2.1 Effect of LPS treatment in TNFα expression 
Production of cytokines, such as TNFα, is elevated during inflammation. To study the 
effect of the increasing dose of LPS in inducing inflammation, a TNFα response profile 
was conducted. 
 
The peripheral TNFα response profile was obtained from blood plasma in which the 
animals were culled two hours after each dose increment or after the final dose. The LPS 
treated animals showed elevated levels of TNFα after the first dose of LPS treatment at 
0.25mg/kg. However, in subsequent treatments, similar TNFα levels were observed in 
both groups, suggesting that TNFα response was abolished by the time the animals 
received the 0.5mg/kg LPS dose (figure 3.22). 
 
The protein level for TNFα in a peripheral organ such as the liver was also obtained. 
When liver samples were obtained 2 hours after the first LPS treatment at 0.25mg/kg, an 
elevated TNFα protein level was detected in the liver (figure 3.23). When liver samples 
were obtained 2 hours after the last LPS treatment at 16mg/kg, there was no significant 
difference in the protein level in both treatment groups (figure 3.24).  Thus, both ELISA 
blood plasma and the protein level showed that only at the 0.25mg/kg and by the end of 
the treatment, the TNFα response was abolished. 
 
To find out if the CNS is affected by LPS induced inflammation, the brain of animals 
treated with either LPS or vehicle were harvested 2 hours after the first dose of LPS at 
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0.25mg/kg and the last dose of LPS at 16mg/kg ten days later. The brain was subdivided 
into two different regions namely the hippocampus and cortex as both brain regions have 
been previously been shown to be involved in learning and memory. The western blot 
data from these brain samples suggest that after the first dose of LPS treatment at 
0.25mg/kg, a significant elevation of TNFα protein was expressed in both the 
hippocampus and cortex (figure 3.25 and 3.27). Peripheral administration of LPS is able 
to elicit an inflammatory response in the CNS. More interestingly, brain samples from 
animals that have completed the ten days dosing regime showed a significant elevation in 
TNFα protein level in both brain regions (figure 3.26 and 3.28). This suggested that there 
may be a differential effect of LPS in CNS and peripheral system. 
 
3.2.2 Effect of LPS treatment in microglia 
Microglia are the prime component of the CNS immune response. Hence, to understand 
the effect of LPS in inducing neuroinflammation in the CNS, the effect of LPS on 
microglia was investigated.  
 
To study the effect LPS treatment may have on microglia, the immunohistochemistry 
staining using CD11B/CD18 was selected as this protein is only expressed by the 
microglia in the CNS. CD11B/CD18 is part of the complement receptor (CR) 3 and is 
also known as the macrophage antigen complex 1 (MAC1). In orchestrating 
inflammation, the MAC1 performs diverse functions involved in adhesion, chemotaxis 
and phagocytosis. Furthermore, its expression has been shown to be elevated in numerous 
neurodegenerative diseases such as AD (Gao and Hong 2008). The hippocampus, 
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especially the dentate gyrus was examined. The immunohistochemistry staining suggests 
that there is an increase expression of CD11b/CD18 as seen from the intensity of the 
staining (figure 3.29).  
 
In addition to immunohistochemistry, Western blot analysis was used to determine the 
CD11B/CD18 protein level in the CNS. Based on the data, it suggests that there is an 
increase expression of MHC II in the cortex and hippocampus (figure 3.30 and 3.31). 
There is evidence to suggest that the peripheral administration of LPS is able to induce 
changes in microglia in which more antigens that implicates the function of microglia as 
antigen presenting cells are expressed.  
 
3.2.3 Effect of LPS on myeloperoxidase activity 
To protect the body against invading microgorganisms, microglia produces free radical 
such as hypochlorite (OCl
-





generation of free radicals require the conversion of hydrogen peroxide by the MPO 
enzyme and has been regarded as a key component of inflammation. 
 
After the first treatment of LPS, there was an increase in the MPO activity in the spleen 
when compared to the naïve animal and in subsequent dose; a lower level of MPO 
activity was observed (figure 3.32). Albeit there is no significant difference observed in 
the data obtained, there is a similar trend observed in the periphery system with the TNFα 
cytokine level expression (figure 3.22) 
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When the activity of the MPO enzyme in the CNS was determine, there was no 
significant difference in the MPO activity in all treatment group, although the LPS treated 
animals did display a trend to an increase in MPO activity in the hippocampus (figure 
3.32). 
 
3.2.4 Effect of Indomethacin in reversing the LPS induced cognitive deficit 
To confirm that the cognitive deficit seen was due to neuroinflammation induced by the 
peripheral LPS administration, animals treated with increasing dose of LPS were treated 
with indomethacin, an anti inflammatory agent. 
 
Similar to results obtained previously (figure 3.12 and 3.13), animals treated with LPS 
performed significantly worse in SC day 1 and in this instance on SC day 2 as well as 
longer time was required to find the platform location (figure 3.33). However animals 
treated with 1mg/kg indomethacin 15 minutes prior to each morning dose of LPS 
treatments no learning and memory deficit was observed. No significant difference was 



















































Figure 3.22 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
TNFα level. Plasma was collected 2 hours after each dose increment. Data points 







































Figure 3.23 Effect of a single dose of 0.25mg/kg of LPS on transmembrane tumour 
necrosis factor (TM TNF) using whole cell lysate samples (3ug/lane) in the liver A) 
representative TM TNF and actin immunoblots B) bar graph showing the ratio of TM 
TNF to actin.  The average intensity of the TM TNF was normalized to the actin band 
from the same sample. Data points represent mean  SEM. Asterisks indicate 















































Figure 3.24 Effect of increasing dose of LPS on transmembrane tumour necrosis factor 
(TM TNF) using whole cell lysate samples (3ug/lane) in the liver A) representative TM 
TNF and actin immunoblots B) bar graph showing the ratio of TM TNF to actin.  The 
average intensity of the TM TNF was normalized to the actin band from the same sample. 
Data points represent mean  SEM.  n=5. 















































































Figure 3.25 Effect of a single dose of 0.25mg/kg of LPS on soluble tumour necrosis 
factor (Sol TNF) and transmembrane (TM) TNF using whole cell lysate samples 
(3ug/lane) in the hippocampus A) representative Sol TNF, TM TNF and actin 
immunoblots B) bar graph showing the ratio of TM TNF and sol TNF to actin.  The 
average intensity of the TM TNF and Sol TNF was normalized to the actin band from the 
same sample. Data points represent mean  SEM.  Asterisks indicate significantly 
























































Figure 3.26 Effect of increasing dose of LPS on TM TNF using whole cell lysate 
samples (3ug/lane) in the hippocampus A) representative TM TNF and actin 
immunoblots B) bar graph showing the ratio of TM TNF to actin.  The average intensity 
of the TM TNF was normalized to the actin band from the same sample. Data points 
represent mean  SEM.  Asterisks indicate significantly different from the vehicle group 
(*p<0.05). n=5. 











                                                           
 
       

































   
 
Figure 3.27 Effect of a single dose of 0.25mg/kg of LPS on TM TNF using whole cell 
lysate samples (3ug/lane) in the cortex A) representative TM TNF and actin immunoblots 
B) bar graph showing the ratio of TM TNF to actin.  The average intensity of the TM 
TNF was normalized to the actin band from the same sample. Data points represent mean 
 SEM.  Asterisks indicate significantly different from the vehicle group (*p<0.05). n=5. 
Cortex 

















































Figure 3.28 Effect of increasing dose of LPS on TM TNF using whole cell lysate 
samples (3ug/lane) in the cortex A) representative TM TNF and actin immunoblots B) 
bar graph showing the ratio of TM TNF to actin.  The average intensity of the TM TNF 
was normalized to the actin band from the same sample. Data points represent mean  
SEM.  Asterisks indicate significantly different from the vehicle group (*p<0.05). n=5. 
Cortex 












    
 
   
 
   
Figure 3.29 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
CD11b expression. Brain samples were collected 2 hours after each dose increment 
where A) vehicle B) 0.25mg/kg LPS C) 0.5mg/kg D) 1mg/kg E) 2mg/kg F) 4mg/kg G) 
















































Figure 3.30 Effect of increasing dose of LPS on major histochemistry complex II using 
whole cell lysate samples (3ug/lane) in the cortex A) representative MHCII and actin 
immunoblots B) bar graph showing the ratio of MHCII to actin.  The average intensity of 
the MHCII was normalized to the actin band from the same sample. Data points represent 
mean  SEM.  Asterisks indicate significantly different from the vehicle group 
(**p<0.01). n=5. 
    Cortex 














































Figure 3.31 Effect of a single acute dose of 16mg/kg of LPS on major histochemistry 
complex II using whole cell lysate samples (3ug/lane) in the hippocampus A) 
representative MHCII and actin immunoblots B) bar graph showing the ratio of MHCII 
to actin.  The average intensity of the MHCII was normalized to the actin band from the 
same sample. Data points represent mean  SEM.  Asterisks indicate significantly 
different from the vehicle group (*p<0.05). n=5. 










































































































































Figure 3.32 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
myeloperoxidase activity in the (A) spleen and (B) hippocampus. Tissue samples were 























































































































Figure 3.33 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) 
and indomethacin (1mg/kg) treatment on animals dosed with increasing dose of LPS on 
(A) escape latency (B) swimming speed and (C) pathlength to find the hidden platform in 
the Morris watermaze test. Data points represent mean  SEM. Asterisks indicate 





3.3 Neuroinflammation induced cognitive impairment: potential mechanisms 
 
3.3.1 Activity-regulated cytoskeleton-associated protein (Arc) 
The immunoblot demonstrated that there was no change in the protein expression of Arc 
protein in the hippocampus (figure 3.34). In the cortex however, a significant decrease in 
Arc protein expression was observed. To confirm that the decrease in protein expression 
observed in the cortex was not due to the reduction in the number of neurons, an 
immunoblot specific for synaptophysin was conducted to ensure that the total number of 
synapses present were similar in both vehicle and LPS treated group. The immunoblot for 
synaptophysin demonstrated that there was no significant difference in the number of 
synapses between the vehicle and LPS treated animals in both hippocampal and cortical 
regions (figure 3.35). 
 
3.3.2 Amyloid precursor protein (APP) 
There was a significant overexpression of APP protein in the hippocampus region. 
However, no significant difference was observed in the cortex (figure 3.36) 
 
3.3.3 Acetylcholine expression 
To determine the effect of LPS treatment on the cholinergic network, the expression of 
vesicular acetylcholine transporter (VAChT) was investigated. Western blotting analysis 
showed a significant increase in the VAChT in the hippocampus, and a decreased 




                                                       
 





























































                                     
Figure 3.34 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
arc using whole cell lysate samples (3ug/lane) in the hippocampus and cortex A) 
representative arc and actin immunoblots B) bar graph showing the ratio of arc  to actin.  
The average intensity of the arc was normalized to the actin band from the same sample. 
Data points represent mean  SEM. Asterisks indicate significantly different from the 
vehicle group (* p<0.05). n=5. 
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Figure 3.35 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
synaptophysin using synaptosome preparation samples (10ug/lane) in the hippocampus 
and cortex A) representative synaptophysin and actin immunoblots B) bar graph showing 
the ratio of synaptophysin  to actin.  The average intensity of the synaptophysin was 
normalized to the actin band from the same sample. Data points represent mean  SEM. 
n=5. 
Synaptophysin 









                                     
                                                                             


































































Figure 3.36 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
amyloid precurosor protein (APP) using whole cell lysate samples (3ug/lane) in the 
hippocampus and cortex A) representative APP and actin immunoblots B) bar graph 
showing the ratio of APP to actin.  The average intensity of the APP was normalized to 
the actin band from the same sample. Data points represent mean  SEM. Asterisks 
indicate significantly different from the vehicle group (* p<0.05). n=5. 
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Figure 3.37 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
vesicular acetylcholine transporter (VAChT) using whole cell lysate samples (3ug/lane) 
in the hippocampus and cortex A) representative VAChT and actin immunoblots B) bar 
graph showing the ratio of VAChT  to actin.  The average intensity of the VAChT was 
normalized to the actin band from the same sample. Data points represent mean  SEM. 
Asterisks indicate significantly different from the vehicle group (* p<0.05).  n=5. 
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3.4 Delayed in cognitive impairment: Possible involvement of neurogenesis 
Although a cognitive deficit was observed as seen in the MWM, NOR and FC 40 hours 
after the last LPS treatment, it was unsure whether the cognitive impairment was only 
limited to the acute state and whether such deficits could still be observed at a later point 
in time. Hence, a time course/protracted study was conducted to study the effect of 
increasing LPS dosing regime in spatial learning and memory task when the animals 
were tested at 2, 4, 6, 8, 12, 16, and 24 weeks after the last LPS treatment. 
 
When the animals were tested 2, 4, and 6 weeks after the LPS treatment, no significant 





 week after LPS treatment, LPS animals showed a significantly higher latency 
on SC day 1 compared to vehicle. No significant difference was observed in swimspeed 




 week, a stronger deficit was observed in LPS animals. On SC day 1, LPS 
animals took a longer time and distance to find the platform. However, like the acute 
cognitive deficits described earlier, no significant deficit was observed in the subsequent 
days (figure 3.42). 
 
When the animals were tested 16 weeks after LPS treatment, although no significant 
difference was observed in latency and pathlength, the LPS treated animals did show a 
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slightly higher latency and pathlength on SC day 1. No significant difference was 
observed in swimspeed (figure 3.43). By the 24
th
 week, no significant difference was 
observed in both treatment groups in all parameters (figure 3.44). 
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Figure 3.38 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) escape latency (B) swimming speed and (C) pathlength to find the hidden watermaze 
platform in the Morris watermaze test 2 weeks after LPS treatment. Data points represent 















































































   







































Figure 3.39 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) escape latency (B) swimming speed and (C) pathlength to find the hidden watermaze 
platform in the Morris watermaze test 4 weeks after LPS treatment. Data points represent 
























































































































Figure 3.40 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) escape latency (B) swimming speed and (C) pathlength to find the hidden watermaze 
platform in the Morris watermaze test 6 weeks after LPS treatment. Data points represent 





















































































































Figure 3.41 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) escape latency (B) swimming speed and (C) pathlength to find the hidden watermaze 
platform in the Morris watermaze test 8 weeks after LPS treatment. Data points represent 
mean  SEM. n=10. 
 





















































































































Figure 3.42 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) escape latency (B) swimming speed and (C) pathlength to find the hidden watermaze 
platform in the Morris watermaze test 12 weeks after LPS treatment. Data points 




















































































































Figure 3.43 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) escape latency (B) swimming speed and (C) pathlength to find the hidden watermaze 
platform in the Morris watermaze test 16 weeks after LPS treatment. Data points 





















































































































Figure 3.44 Effect of increasing dose of LPS (0.25-16mg/kg, twice daily for ten days) on 
(A) escape latency (B) swimming speed and (C) pathlength to find the hidden watermaze 
platform in the Morris watermaze test 24 weeks after LPS treatment. Data points 












4.1 Identification of suitable dosing regime to induce cognitive deficit 
Earlier experiments conducted using the peripheral administration of LPS had shown 
inconclusive results as to whether peripheral treatment of LPS is able to elicit a cognitive 
deficit in rodents. One possible reason that may explain the varying outcomes is that the 
behavioural testings in the earlier experiments were conducted two to six hours after LPS 
treatment, a period when animals were exhibiting varying degrees of sickness behaviour. 
These behaviours only appear two to four hours after injection, last for four to six hours 
and dissipate by 24 hours (Danzter 2004). Hence, to investigate if systemic inflammation 
is able to induce cognitive deficits, behavioral tests should only be conducted when rats 
were devoid of any sickness behaviour. Preliminary studies have demonstrated that a 
single dose of LPS at 1mg/kg was insufficient to induce any changes in the performance 
of rodents in the MWM and NOR (figure 3.1 and 3.2) (Arai 2001, Sparkman et al. 2005). 
Therefore it is perhaps not unexpected that the current data indicating a single IP dose 
was insufficient to induce spatial cognitive impairment, seem to contradict previous 
findings where tests were conducted several hours after LPS treatment (2-6 hours) (Arai 
2001, Sparkman et al. 2005). However, these earlier tests were conducted several hours 
after LPS treatment (2-6 hours) while animals were still suffering from the side effects of 
LPS treatment. Our LABORAS™ data has shown that rats were behaving differently at 
two hours after LPS treatment. The changes occurring during this period of time could 
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influence how these animals encode and form new memories. For instance, the reduction 
in motivation as a consequence of sickness behaviour, could easily affect the 
performance of the animals due to reduction in attention and motivation. The lack of 
motivation and attention could hence easily be misconstrued as a cognitive deficit. It is 
vital that when performing any cognitive tests, animals should be devoid of any potential 
side effects that could affect their normal behaviour. 
 
Direct administration of LPS into the CNS has been shown to induce cognitive 
impairment (Hauss-Wegrzyniak et al.1998), suggesting that inflammation induced by 
LPS was able to elicit cognitive deficits. The lack of efficacy seen in peripherally 
administered LPS in inducing cognitive deficits suggests that there were insufficient LPS 
in the peripheral system to drive the neuroinflammation required in inducing changes in 
the CNS. In subsequent studies, multiple doses of LPS were given in order to increase the 
exposure of the immunogenic stimuli in rats. When the LPS treatment was increased to 
three and twenty doses of LPS at 1mg/kg, no cognitive deficits were observed in the 
water maze. The lack of cognitive impairment even with the increased LPS exposure 
suggests that by using a constant dose, the animals were able to develop a tolerance to the 
LPS. A reduction in pro-inflammatory cytokine release is normally observed when the 
body begins to tolerate the endotoxin (Broad et al. 2006). The reduction in pro-
inflammatory cytokines, a potential driver in inducing cognitive deficits in rodents, may 
curtail any effect of neuroinflammation induced changes in the memory systems.  
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There arises a scenario in which to induce a cognitive deficit detectable using rodent 
models, the ideal dosing regime has to fulfil several basic requirements. Firstly, sufficient 
amount of LPS must be administered to drive the desired cognitive deficit. Secondly, 
endotoxin tolerance is known to be a consequence of repeated dosing. The new dosing 
regime would need to overcome this phenomenon in a manner where the tolerance 
developed to sickness behaviour could be maintained but at the same time the effect of 
LPS in inducing changes in learning and memory systems in the CNS could be 
potentiated. 
 
With these requirements in mind, a subchronic increasing dose regime was identified and 
used (adapted and modified from Chen et al. 2005). In order to ensure sufficient exposure 
to LPS, the concentration of LPS administered was increased with time, thus increasing 
the amount of circulating endotoxin in the system that could ultimately induce 
pathological changes in the CNS without building tolerance in the CNS.  
 
Under this dosing regime, the LPS treated animals showed spatial learning and object 
recognition deficits. This is the first report that demonstrated an object recognition 
memory deficit after peripheral administration of LPS. It was previously reported that a 
10 day infusion of LPS into the fourth ventricle failed to induce an object recognition 
deficit (Hauss-Wegrzyniak et al. 2000). The disparities could be explained by the manner 
in which the experiments were conducted. In the current experiment, Lister-hooded rats 
were tested 1 hour after the T1 trial while Hauss Wegrzyniak et al. (2000) had tested the 
Sprague Dawley rats 24 hours after T1. However, based on in-house data (at GSK), most 
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normal and untreated Lister-hooded rats were unable to recall and discriminate the novel 
from the familiar objects 24 hours after T1. Hence the 1 hour delay was chosen over the 
24 hours. The difference in rat strains and the time point in which the T2 trials were 
conducted may also have contributed to the observed disparities.  
 
In a cued fear conditioning (FC) test, rodents are required to learn the association 
between CS (tone) to the aversive US (footshock). The amygdala, hippocampus and 
sensory neocortical areas are believed to be important in cued FC, with lesions of 
amygdala interfering both cued and contextual FC, while lesions in the hippocampus only 
affects the contextual FC (Philips and LeDoux 1992). The increasing dose of LPS 
treatment did not induce a significant deficit in cued FC as the LPS treated animals 
performed similarly to the vehicle treated animals. This suggests that the LPS treatment 
may not have an effect on the amygdala and other associated brain regions (figure 3.16).  
 
When the animals were tested in contextual fear conditioning test, a test that is 
hippocampus-dependent (Philips and LeDoux 1992), both treatment groups spent similar 
amount of time freezing in the first four minutes during the recall trial. However, a 




 minute. The vehicle 
treated animals showed a significantly lower percentage of time spent freezing compared 
to the LPS treated animals. As no reinforcing stimulus was presented to strengthen the 
fear-stimulus association, the vehicle group was able to reverse the association. The LPS 
treated animal however, froze for more than 50% of the time (figure 3.16). The 
persistently higher amount of freezing time could be due to the alteration in neural 
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networks due to LPS. LPS treatment had encoded the association between the 
environment and the shock strongly and more time is required to dissociate the learned 
association. Alternatively, the inability of these rats to forget the association suggests a 
potential reversal learning deficit. However, as reversal learning deficits are not routinely 
detected using the contextual FC paradigm, more experiments are needed to test this 
hypothesis.  
  
No significant difference was observed in the overall behaviour and motor coordination 
during the time of the test, confirming the absence of sickness behaviour. The increasing 
dose of LPS treatment however did induce a significant change in body weight. The 
initial weight loss was attributed to the reduction in food consumption induced by an 
increase in sickness behaviour response after LPS treatment. At the higher dose of LPS, 
the weight of animals although did not show an increase as compared to the vehicle 
treated animals, there was no reduction in weight at the same time (figure 3.21). 
Response to an endotoxin insult is phasic in nature divided by the acute and chronic 
phases of the insult (Rudiger et al. 2008). The initial acute phase is normally 
accompanied by pro-inflammatory activity that leads to an increase in endocrine, 
thermogenic and metabolic activity, excessive catabolism and fuel utilisation. The 
subsequent stage, the anti-inflammatory phase, an evolutionary mechanism to prevent 
excessive damage induced by the pro-inflammatory agents, is normally associated with 
bioenergetic failure and a reduction of metabolic rate (Rudiger et al. 2008). Thus the 
reduction in food intake at higher doses of LPS could be reflective of the reduction in the 
metabolic rate.  
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4.2 Systemic inflammation induced inflammation in the CNS 
4.2.1 TNFα expression in the CNS and the periphery 
TNFα level in the liver demonstrated a classical bi-phasic inflammatory reaction to an 
endotoxin insults (Rudiger et al. 2008); an acute proinflammatory phase, as seen by the 
elevated levels of TNFα in plasma and liver, and a chronic anti inflammatory phase, as 
seen by the lack of TNFα production in subsequent dose. In the CNS however, both 
hippocampus and cortex showed elevated protein expressions even after the completion 
of the ten days dosing regime. The differential response suggests a divergent effect of 
chronic inflammation in the peripheral system and CNS. The reason of these differential 
responses is unknown but they could possibly be explained by the different levels of 
tolerance to the endotoxin insult (Ru et al. 2004). The elevated TNFα seen in the brain 
however suggests neuroinflammation was occurring in the brain at the time of testing. 
 
Several mechanisms have been suggested to be involved in the regulation of the brain 
cytokine levels in peripheral inflammation (Turrin et al. 2001). A possible mechanism 
involves the transfer of intermediate soluble factors such as prostaglandins or cytokines 
across the blood brain barrier (BBB) and/or circumventricular organs where the BBB is 
sparse. A second possible mechanism involved the production of pro-inflammatory 
cytokine by the circumventricular organs directly activated by peripheral inflammatory 
factors. Finally, a third possible mechanism involves neural afferent signalling that leads 




4.2.2 Changes in the microglia in the CNS 
The dentate gyrus, part of the hippocampal formation, is believed to be important for 
normal functioning of the hippocampus as the dentate gyrus is the primary input into the 
hippocampal formation after receiving inputs from the entorhinal cortex (Li and Pleasure 
2005). In addition, the dentate gyrus is also one of the two known regions in the CNS that 
undergoes neurogenesis. Recent experiments have shown that new born cells were vital 
in spatial and object recognition memory in adult rats (Jessberger et al. 2009).  
 
In order to determine the effect of neuroinflammation on the hippocampus, in particular 
the dentate gyrus region, the microglia expression was examined using the CD11B/CD8 
epitope. The CD11B/CD18, a CR 3 complex marker that is specific for microglia was 
chosen to examine the microglia distribution in the dentate gyrus. Based on the 
immunohistochemistry data, CD11B/CD18 expression seems to be upregulated in the 
dentate gyrus of the LPS treated animals as the intensity of the stain is stronger compared 
to the vehicle treated animals (figure 3.29). During inflammation, the CD11B is 
upregulated and an increase in intensity and number were observed when compared to 
normal healthy animals. 
 
In addition to the elevated expression of CD11B/CD18 complex, the activation of 
microglia and astrocytes may also be characterized by the increased expression of MHC 
class I and II in addition to the cytokine production. In microglia, which acts as the main 
resident antigen presenting cells, MHC class I and II are upregulated to initiate immune 
response via T-cells (Dimayuga et al. 2005). Similar to the CD11B/CD18 expression 
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after the completion of the increasing LPS dose regime, the LPS treated animals showed 
a significantly higher amount of MHCII in the cortex and hippocampus, suggesting a role 
for the microglia to act as antigen presenting cells during chonic inflammation (figure 
3.30 and 3.31). The increased expression of inflammatory markers such as CD11B/CD18 
and MHCII suggests that the peripheral administration of LPS could trigger the 
upregulation of these pro-inflammatory molecules. 
 
4.2.3 Myeloperoxidase activity 
MPO is a glycosylated, heme enzyme found in the azurophilic granules of neutrophils 
and is commonly used as a histopathological marker for neutrophils (Breckwoldt et al. 
2008). It is expressed in the myeloid line, including cells such as microglia. In recent 
years, the MPO has been used as a biomarker for inflammation as it is known to be 
upregulated in “diseased” brains but this enzyme is rarely expressed in normal brain 
microglia (Lefkowitz and Lefkowitz 2008). 
 
The spleen MPO activity displayed a similar TNFα profile, again suggesting a biphasic 
reaction to the increasing LPS dosing regime. The insignificant level of MPO activity 
observed in the hippocampus in the LPS animals however was in parallel with the 
immunohistochemistry data. Elevated level of MPO is commonly produced by activated 
microglia. Although some microglia in the dentate gyrus exist in the ameboid shape, the 
majority of the microglia present were in the ramified state. The cognitive impairment 
observed in LPS treated rats could thus be induced by other mechanism beside damages 
induced by oxidative stress. 
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4.2.4 Effect of indomethacin on the increasing LPS dosed animals. 
To ascertain whether the cognitive deficits seen in rodent learning and memory tasks 
were induced by neuroinflammation, the effect of anti-inflammatory drug, such as 
indomethacin, was investigated. Indomethacin, a non-steroidal anti-inflammatory drug 
(NSAID) that inhibits COX, is commonly used in treatment for inflammation and pain. 
COX, especially COX 2, has been shown to be a downstream protein produced by glial 
cells after inflammatory stimuli such as LPS and Aβ peptides (Melnikova et al. 2006). 
COX 2 is the inducible isoform of COX 2 and can be regulated by synaptic plasticity 
(Chen et al. 2002), whereas COX 1 is constitutively expressed in cells. In COX 2 
transgenic mice, as the animal ages, an increase in cortical neuronal apoptosis and glial 
activation that goes hand-in-hand with cognitive impairment was observed (Andreasson 
et al. 2001). Therefore in order to determine whether the deficits were indeed related to 
inflammation, the inhibition of a downstream protein such as COX2, would demonstrate 
an amelioration of the deficits seen by using the increasing LPS dosing regime. 
 
Rats that were treated with indomethacin prior to the LPS treatment showed a reversal of 
the cognitive deficits induced by the LPS treatment as they performed as well as the 
vehicle treated animals. Indomethacin penetrates the BBB readily (Parepally et al. 2006), 
thus allowing the anti-inflammatory agent to act directly in the peripheral system and the 
CNS. Current results which demonstrate the ability of indomethacin to reverse the 
neuroinflammatory process and abolish the learning and memory deficit, further 
strengthen the hypothesis that the cognitive deficits observed in LPS treated animals. 
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4.3 Inflammation induced cognitive deficit 
4.3.1 TNFα induced cognitive deficit 
TNFα is a member of the TNF superfamily of ligand that promotes inflammatory 
signalling (McCoy and Tansey 200). Existing as type-2 transmembrane protein (tmTNF) 
or soluble circulating trimer (solTNF), both types have been shown to be biological 
active and found to be released in the CNS by microglia, astrocytes and neurons 
(Morganti-Kossman et al. 1997). Both tmTNF and solTNF regulate cellular processes 
such as inflammation, differentiation and cell death through the activation of TNF 
receptor 1 or 2 via mitogen-activated protein kinases (MAPKs) and IκB kinase by 
modulating transcriptional factors such as activator protein-1 (AP-1) and NFκB that 
inevitably affects gene transcription (Medeiros et al. 2007). 
 
Toxic concentration of TNFα can lead to excessive activation of NMDA receptors, which 
in turn results in excitotoxicity induced neuronal death. TNFα has also been reported to 
potentiate glutamate neurotoxictiy by inhibition of glutamate transport by predominantly 
inhibiting GLT1 via the NFκB signaling pathway transport in both neurons and astrocytes 
(Zou and Crews 2005). Glutamate transporter (GLT) 1 is predicted to contribute up to 
90% of glutamate transport in certain brain regions. These transporters have been shown 
to contribute to glutamate synaptic signal termination, to recycle glutamate and maintain 
the glutamate concentrations below the excitotoxic threshold (Sims and Robinson 1999). 
As TNFα induces an inhibition in the glutamate transport, increased glutamate levels in 
the synaptic cleft may induce a spill over, allowing excess glutamate to bind to the 
extrasynaptic NMDA receptors. Activation of extrasynaptic NMDA receptors has been 
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suggested to lead to excitotoxicity (Hardingham et al. 2002). These receptors have an 
opposite effects on cAMP response element binding (CREB) function where CREB has 
been shown to be necessary for gene regulation and neuronal survival. The activation of 
these receptors ultimately leads to the loss of mitochondrial membrane potential and 
neuronal death (Hardingham et al. 2002). 
 
One possible mechanism through which the elevation of TNFα may induce cognitive 
impairment is via the generation of excessive NO. The generation of NO by iNOS has 
been shown to involve the activator protein-1 (AP-1) pathway. AP-1 is a transcriptional 
factor composed of the protein products of c-jun and c-fos (Angel and Karin 1991). The 
sustained activation of the AP-1 and jun-N terminal kinase (JNK) pathway induced by 
TNFα signalling has been demonstrated to induce iNOS upregulation (Zou and Crews 
2005). Furthermore, to strengthen the association between TNFα signalling and iNOS, 
molecular cloning and analysis, have reported that the promoter region of iNOS gene 
consists of binding sites to several transcription factors such as AP-1, NFκB and TNF 
response element. This strengthens a possible link between TNFα levels and iNOS 
transcription (Eberhardt et al. 1996). The predominant mechanism through which NO 
promotes neuronal toxicity is through the reaction of NO with superoxide anion to 
generate cytotoxic substance peroxynitrite (Eberhardt et al. 1996).). During inflammation, 
excessive accumulation of NO will lead to cellular dysfunctions and cell death. In fact, in 
AD patients where neuroinflammation is prevalent, increased expression of iNOS and 
peroxynitrite damage have been reported (Zou and Crews 2005). 
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TNFα has been shown to reduce neurite outgrowth and branching in hippocampal 
neurons via small guanosine triphosphatase (GTPase) Rho (Neumann et al. 2002). The 
Rho GTPases activity has been shown to be important for the signal transduction between 
membrane proteins and actin cytoskeleton (Hall 1998). The direct mechanism through 
which TNFα interfere the Rho GTPase activity is unknown. However there is evidence 
that suggest the involvement of NO and/or NO-derived products (Münch 2003). During 
neuroinflammation, the elevation of TNFα may affect neurite elongation, possibly 
serving as an anti-regenerative factor in addition to other growth inhibition factors such 
as Nogo and glial scars (Neumann et al. 2002). This would also prevent the repair of 
damaged neural networks that could be vital for learning and memory. 
 
4.3.2 Activity-regulated cytoskeleton-associated protein (Arc) 
Arc or Arg3.1, is part of the immediate early genes (IEG) family. Transcription of Arc 
correlates both temporally and spatially with activity induced stimulus (Rosi et al. 2008). 
This gene is highly conserved in vertebrates and biochemical studies have demonstrated 
that Arc protein coprecipitates with polymerized actin that is extensively found in 
dendritic spines (Bramham et al. 2008). Since then, Arc protein has been identified to 
play a vital role in the maintenance phase of LTP and spatial memory compression (Rosi 
et al. 2008). It regulates glutamate transmission mediated by controlling the α-amino-3-
hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor trafficking via its interaction 
with components of the endocytic machinery such as dynamin and endophilin 
(Chowdhury et al. 2006). Overexpression of Arc induced a reduction in surface 
expression of GluR1-containing AMPA receptors, while Arc null primary neurons 
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showed an elevated surface expression of AMPA receptors (Centonze et al. 2009). More 
interestingly, in AD patients with pronounced deficits in hippocampus-dependent 
memory functions, an almost 3.5 decrease in the baseline level of Arc expression was 
observed when compared to non-AD patient (Rosi. et al. 2008).  
 
Recently, it has been reported that centrally injected LPS in mice resulted in a lower 
expression of Arc in the cortex but not hippocampus (Bonow et al. 2009). These results 
are consistent with the current finding in which the increasing LPS dosing regime was 
able to elicit a reduction of Arc protein in the cortex but not hippocampus. This change 
was independent of synapse number as similar levels of synaptophysin were observed.  
 
The exact mechanism that induced a reduction of the Arc protein level has not been fully 
elucidated. The reduction in the cortical level could be attributed to the decrease 
expression of the Arc mRNA or alterations in proteosome processing that could increase 
the rate of degradation of Arc proteins in dendritic spines. Arc protein level was not 
reduced in the hippocampus. This may suggest higher tolerance to LPS insult in the 
hippocampus or alternatively, other compensatory mechanisms were available to prevent 
the changes in the neural network. 
 
Nonetheless, there exists a possible association between the change in Arc protein 
expression and the cognitive impairment observed. The two pathways that are involved in 
the induction of Arc are the activation of glutamatergic synapses and the release of brain-
derived neurotrophic factor (BDNF) (Spulber et al. 2008). In the glutamatergic pathway, 
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the activation of the NMDA receptors upregulates Arc while stimulation of the AMPA 
glutamate receptor downregulates Arc (Rao et al. 2006, Shepherd et al. 2006). 
Furthermore, changes in Arc level are also dependent on the NMDA/AMPA receptor 
ratio that could in turn enhance negative feedback control of Arc expression, thus 
influencing the transcription of Arc (Rosi et al. 2008). TNFα has been shown to modulate 
the expression of AMPA. The application of TNFα increases the expression of the 
surface AMPA receptors (AMPAR) in the plasma membrane in hippocampal neuronal 
culture (Beattie et al. 2002). As demonstrated previously, TNFα was elevated in the 
cortex when animals were given the increasing doses of LPS, suggesting that the 
reduction in the Arc protein expression could be linked to the elevated TNFα expression 
seen in the cortex. During inflammation, TNFα could induce an increase in the 
expression in the AMPAR on the surface of dendritic spines that ultimately changes the 
NMDA/AMPA receptor ratio, suppressing the expression of Arc in the cortex. 
 
On the other hand, the expression of Arc has also been shown to be stimulated by BDNF 
(Rosi et al. 2008). BDNF belongs to the neurotrophin family of growth factor which has 
been shown to regulate synaptic transmission in the brain such as LTP and long term 
depression (LTD) (Schnydrig et al. 2007). In rodents that were peripherally treated with 
LPS, a decreased level of BDNF was observed in the brain (Schynydrig et al. 2007). 
Physical activity is able to reverse this (Wu et al. 2007). Hence, the reduction in Arc 
expression could be attributed to the reduction of neurotrophic factors such as BDNF 
when animals were injected using the increasing LPS dose regime. 
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In addition, as a member of the IEG family, Arc can also serve as a marker for neural 
activity (Bonow et al. 2009). The reduction of Arc in cortex could be a consequence of 
diminished neural activity. In an electrophysiology study, Vereker et al. (2000) has 
demonstrated that when animals were dosed with LPS, there was a significantly drop in 
glutamate released, suggesting a suppression of the excitatory neurotransmission. The 
reduction in Arc level could be a reflection of diminishing neural activity as LPS has 
been shown to cause the reduction of glutamatergic transmission.  
 
Arc has been demonstrated to play an important role in LTP and is normally expressed 
within minutes after being subjected to a cognitive task. It will be interesting to 
investigate the Arc expression level when the LPS treated animals were subjected to a 
cognitive task. The reduction in the basal level of Arc may explain the acute deficits seen 
in learning and memory tasks as an increased amount of Arc is needed to be produced to 
achieve levels required for learning and memory processes.  
 
4.3.3 Amyloid precursor protein (APP) 
It has been recently suggested that peripheral administration of LPS could induce a 
cognitive impairment in passive avoidance and water maze tests in mice through the 
enhancement of Aβ generation (Lee et al 2008). Consistent with the current data, an 
increase expression of APP in the hippocampus and not cortex were observed in animals 
treated with LPS. In addition, Lee et al. (2008) also demonstrated that accompanying the 
elevation of APP, an accumulation of Aβ1-42 was observed in the hippocampus together 
with the increase in β- and γ-secretase activities. This suggests that processes of 
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amyloidogenesis may also contribute to the cognitive impairment observed in LPS 
animals.  
 
The exact mechanism through which peripheral LPS administration could lead to the 
elevation of APP and generation of Aβ in the hippocampus is still unknown. However it 
was postulated that amyloidogenesis induced by LPS treatment could involve the 
activation of AP-1 via TNFα, as a potential activator of AP-1 recognition site was 
detected in the gene (Quitschke and Goldgaber 1992). Furthermore, LPS has been shown 
to increase MAPK activity, a signalling pathway that has been implicated in AD (Lee et 
al. 2008). 
 
Using whole cell recording and immunocytochemistry, APP has been shown to induce 
synaptic depression via a selective reduction of AMPAR (Ting et al. 2007). As described 
earlier, Arc is also involved in the endocytosis of AMPAR. However, as the immunoblot 
data showed no elevation of Arc protein in the hippocampus, it is likely that the 
endocytosis process can be induced by another mechanism. One possible mechanism of 
inducing an increase in the endocytosis of AMPAR is by PSD-95 which is a protein 
involved in recruiting and anchoring glutamate receptor subunits. A reduction in the 
PSD-95 expression has been linked to a reduction in the AMPAR in cell surface of APP 
mutant mice (Almeida et al. 2005). Conversely, an overexpression of PSD-95 led to an 
increase surface expression in AMPA in vitro (Bhattacharyya et al. 2009)  
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Not limiting to the post synaptic terminal, APP via the generation of Aβ induces a deficit 
in vesicle recycling during sustained stimulation. The disruption of vesicle recycling 
could be linked to the reduction in dynamin 1, a GTPase responsible for pinching off 
synaptic vesicles during endocytic retrieval from the plasma membrane (Ting et al. 2007). 
In AD brains, levels of dynamin 1 were reported to be significantly reduced as well (Yao 
et al. 2003) and Aβ application in cultured hippocampal neuron also significantly reduces 
dynamin level (Kelly et al. 2005). 
 
More work is required to determine whether the overexpression of APP seen in the 
hippocampus would be translated to an increase in deposition of Aβ. However, it is 
interesting to note that the overexpression of APP was only observed in the hippocampus 
but not in the cortex; while reverse was true for the reduction of Arc in hippocampus. 
More interestingly, the overexpression of APP is associated with the increase 
internalisation of AMPAR while the reduction of Arc is linked to the overexpression of 
AMPAR in dendritic spines (Centzone et al. 2009). Albeit such differences in 
mechanisms, both ultimately could lead to the impairment in the learning and memory 
paradigm. 
 
4.3.4 Vesicular acetylcholine transferase (VAChT) 
In recent years, the cholinergic innervations in the CNS have been implicated as a 
potential mechanism to counteract excessive production of pro-inflammatory cytokines in 
addition to its role in attention and learning and memory (Nicolussi et al. 2009). The 
activation of nAChRα7 on non-neuronal cytokine producing cells has been shown to 
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inhibit the overproduction of inflammatory cytokines (Pavlov and Tracey 2006). 
Interestingly, when a high dose of LPS was administered peripherally to mimic sepsis, 
substantial loss of neurons and cholinergic innervations was observed in different brain 
regions (Semmler et al. 2007). 
 
In order to determine the effect of the increasing concentration of LPS has on the 
cholinergic innervation in the cortex and the hippocampus, the VAChT was chosen to 
label cholinergic terminals. The VAChT is a more specific marker in revealing the 
cholinergic networks rather than the acetylcholinesterases since the latter has been found 
in cholinergic and cholinoceptive neurons whereas VAChT is exclusively found in the 
synaptic terminal of cholinergic neurons (Wong et al. 1999). 
 
Interestingly, the Western blot analysis demonstrated differential effects in the results 
between the hippocampus and cerebral cortex. An increase in VAChT expression was 
observed in the hippocampus while a decrease was noticed in the cortex (figure 3.37). 
The reduction of the VAChT expression in the cortex is in agreement with the loss of 
cholinergic innervations as reported previously by Semmler et al. (2007). In AD patients 
where neuroinflammation is prevalent, it is normally defined by a massive loss of the 
cholinergic innervations especially in the basal forebrain. This strengthens the hypothesis 
that the neuroinflammation precedes the cholinergic loss in AD. 
 
In transgenic animals that are overexpressing the mutated form of APP (APPC695T), an 
increase in cholinergic synaptic density was also reported by elevated levels of VAChT 
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in affected brain regions (Wong et al. 1999). Although the physiological function of APP 
is unknown, it has been postulated to have trophic properties. Hence in brain regions that 
are overexpressing APP, there could be not only an increase in the production of 
potentially toxic Aβ peptides, but also the secretion of the neurotrophic APP region as 
well (Wong et al. 1999). Consequently an upregulation of cholinergic synapses could be 
observed. Alternatively, the upregulation of the VAChT could be linked to a sustained 
inhibition of the cholinergic function as Aβ peptides have been shown to potently inhibit 
the K
+
-evoked acetylcholine release from hippocampal slices. The sustained inhibition 
could induce a transient compensatory changes or sprouting of the cholinergic network 
(Wong et al. 1999). The increase in the VAChT seen could hence be associated with the 
increased expression of APP in the hippocampus. 
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4.4 Effect of LPS on neurogenesis 
Neurogenesis, a process of generating functionally integrated neurons from progenitor 
cells, occurs in regions such as the subgranular zone (SGZ) of the dentate gyrus (Ming 
and Song 2005). Within 3 weeks, most of these newborn neurons become integrated into 
existing dentate gyrus circuitry, receiving excitatory synaptic input from perforant path 
afferents and transmitting signals along the axons to CA3 (Kee et al. 2007). 
 
The field of neurogenesis and its correlation with cognitive functions has remained 
controversial. However, there is evidence to suggest that neurogenesis could be related to 
learning and memory. Irradiation has been shown to block neurogenesis and lead to 
deficits in learning and memory (Wu et al 2007). It was recently reported that some of the 
new neurons were incorporated into the dentate gyrus circuits to support spatial memory 
function in an age-dependent manner. The recruitment of new neurons did not occur until 
they are at least 2 weeks old. By 4 weeks, new neurons were more likely than mature 
neurons to be recruited into the dentate gyrus circuits (Kee et al. 2007) as they showed 
decreased threshold plasticity (Schmidth-Heiber et al. 2004). 
 
Chronic neuroinflammation may invariably have a negative effect on neurogenic 
processes. In adult transgenic mice with chronic astrocytic production of IL-6, it was 
reported that the overall neurogenesis in the hippocampal dentate gyrus decreased by 
63%, where the proliferation, survival and differentiation of the neural progenitor cells 
were significantly reduced in the granule cell layer (Vallières et al. 2002). A single 
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1mg/kg LPS IP administration also demonstrated a 35% decrease in hippocampal 
neurogenesis and could be reversed by treatment using NSAID (Monje et al. 2003).  
 
Thus, the cognitive impairment observed using the increasing LPS dose concentration 
seems to suggest that the delayed effect could be linked to the disruption of neurogenesis. 
As reported previously (Kee et al. 2007), there exist a critical period in which the 
disruption of neurogenesis by neuroinflammatory processes could induce a cognitive 
deficit. Based on current results, this critical period lies between 8 to 12 weeks post LPS 
treatment. When animals were tested beyond this time window, no cognitive impairment 
was observed. However, Kee et al. (2007), reported that the preferential recruitment of 
these newborn neurons in spatial memory begins at 2 weeks and peaks at 4 weeks. The 
cause of this discrepancy is still unclear. 
 
There are several hypotheses on the relationship between neuroinflammation and 
neurogenesis. One of these is that the stimulation of the HPA stress axis with the 
elevation of glucocorticoids, leading to the alterations in the relationship between 
progenitor cells and cells of the neuro-vasculature (Monje et al. 2003). Glucocorticoids 
levels were previously measured by Chen et al. (2005) where the increasing LPS dosing 
regime was adapted and modified, had reported elevated glucocorticoids levels in animals 
treated with this dosing regime. The elevated glucocorticoids level may be the underlying 
reason to the disruption of neurogenesis. 
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Furthermore, proinflammatory cytokines especially IL-6, have been shown to induce a 
non-specific decrease in cell survival and a decrease in the accumulation of neurons 
specifically in vitro. The decrease in the number of neurons has been linked to the 
reduction in neuronal differentiation (Monje et al. 2003). The inflammatory mediators 
such as IL-6, TNFα and IL-18, in addition to preventing neuronal differentiation, have 
been reported to induce an increase in glial differentiation (Liu et al. 2005, Cacci et al. 
2008). Thus, systemic administration may not only induce an overall decrease in cell 
proliferation in the dentate gyrus, but it may affect the differentiation of cells to the 
neuronal pathway. With more progenitor cells showing preference to commit to the glial 
pathway, the number of available new neurons to be preferentially recruited to form the 
spatial map is significantly reduced.  
 
LPS administration has been reported to induce a reduction of BDNF (Wu et al. 2007). 
The BDNF signalling pathway includes the expression level of TrkB, has been shown to 
modulate cell survival (Sairanen et al. 2005). The reduction of cell survival signals could 
ultimately lead to the alteration in neurogenesis. 
 
While neurogenesis may offer a possible explanation on the deficits seen when LPS 
animals were tested at 8 and 12 weeks after treatment, experimental evidence is required 
to support this hypothesis. Another possible mechanism that may induce the deficit seen 
could be due to the long-term consequences of sepsis induced by LPS treatment. 
Semmler et al. (2007) have shown that when rats injected with a single acute dose of 
10mg/kg LPS displayed memory deficits in the radial maze three months after treatment. 
 116 
The deficits seen by Semmler et al. (2007) were associated with a reduction of neurons in 
the prefrontal cortex and hippocampus in addition to a reduction by the cholinergic 
innervations in the parietal cortex. Hence, it would be interesting to investigate whether 
similar changes in the hippocampus and prefrontal cortex could be seen in rats that were 






The purpose of the current study was to investigate the effect of neuroinflammation 
induced by peripheral administration of LPS on learning and memory. Initial studies were 
conducted to determine a suitable dosing regime to induce cognitive impairment. 
Peripheral administration of LPS using the increasing LPS dosing regime was able to 
induce deficits in spatial learning and object recognition tasks. Furthermore, impairment 
in reversal learning was also demonstrated using FC. As no significant difference was 
observed in the side-effect profiling tasks, these cognitive impairments were not induced 
by sickness behaviour. 
 
Peripheral administration of LPS was shown to be able to induce an inflammatory 
response in the CNS as elevated TNFα and MHCII levels were observed. These 
proinflammatory mediators produced in response to LPS are hypothesised to affect 
cognition. Cytokines such as TNFα have been shown to be able to affect learning and 
memory processes such as LTP by affecting glutamatergic transmission in terms of 
receptor numbers (Vereker et al. 2006), transporters (Zou and Crews 2005) and glutamate 
release (Vereker et al. 2006). Furthermore, excessive glutamate present in the synaptic 
cleft due to the alteration in transmission is able to induce exitotoxicity (Hardingham et al. 
2002). Not limiting to glutamatergic transmission, LPS treatment has also been shown to 
affect cholinergic innervations. The reduced expression of VAChT in the cortex 
 118 
suggested a loss of cholinergic innervations. The loss of cholinergic innervations suggests 
that in AD, neuroinflammation precedes the occurrence of cognitive deficits and neuronal 
loss in the basal forebrain. 
 
 These proinflammatory mediators are also able to affect synaptic plasticity as the 
translation of proteins belonging to the IEG family such as Arc was shown to be 
decreased when tested 40 hours after the treatment in the hippocampus. As IEG are 
indicative of neuronal activity (Vereker et al. 2000), the reduction of Arc expression in 
basal levels suggests that there is an alteration in the neuronal activity after the LPS 
treatment.  In addition, cytokines such as TNFα has been suggested able to affect neurite 
outgrowth as well (Neumann et al. 2003).  
 
Deficits induced by the LPS treatment were also detected at 8 and 12 weeks post LPS 
treatment. The delayed impairment observed suggest a possible disruption in the 
neurogenesis processes induced by the LPS treatment. Although it remains to be 
controversial, new born neurons were hypothesised to be preferentially recruited during 
learning and memory processes (Kee et al. 2007). Unfortunately, inflammation has been 
shown to affect these new born neurons in terms of cell survival (Sairanen et al. 2005) 
and in cell differentiation where progenitor cells were more likely to enter the glial cell 
pathway (Monje et al. 2003). The alteration in these neurogenesis processes could be 
attributed to the excessive production of proinflammatory cytokines and glucocorticoids 
and the reduction of neurotrophic factors such as BDNF. 
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Neuroinflammation, hence could potentially have two phases on cognition. On one hand, 
immediate effect of the LPS treatment could be detected within 40 hours after the last 
treatment by affecting glutamatergic and cholinergic transmission as well as synaptic 
plasticity. On the other hand, the LPS treatment could induced a delayed cognitive 
impairment as demonstrated when the rats were tested 8 to 12 weeks after LPS treatment 
induced by an alteration in the neurogenesis process. Therefore, in patients suffering from 
neurodegenerative diseases with a prevalent neuroinflammation, the cognitive 
impairment could thus be a complex interaction between the immediate and delayed 
effects of neuroinflammation. Treatment of anti-inflammatory agents such as 
indomethacin, however, was shown to be effective in reversing the effect of the 
neuroinflammation induced cognitive deficits when tested 40 hours after treatment. This 
suggests that anti-inflammatory agents may potentially be effective in treating patients 
suffering from cognitive impairment such as in AD and MCI. In conclusion, the current 
study illustrates the detrimental effect of neuroinflammation on cognition and the 
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